WO2012107589A1 - Méthodes et compositions pharmaceutiques pour le traitement et la prévention des infections à vhc - Google Patents

Méthodes et compositions pharmaceutiques pour le traitement et la prévention des infections à vhc Download PDF

Info

Publication number
WO2012107589A1
WO2012107589A1 PCT/EP2012/052398 EP2012052398W WO2012107589A1 WO 2012107589 A1 WO2012107589 A1 WO 2012107589A1 EP 2012052398 W EP2012052398 W EP 2012052398W WO 2012107589 A1 WO2012107589 A1 WO 2012107589A1
Authority
WO
WIPO (PCT)
Prior art keywords
hcv
binding
hepatocytes
envelope glycoprotein
inhibit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2012/052398
Other languages
English (en)
Inventor
Hicham BOUHLAL
Christele OSSART
Flora CARTIER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Picardie Jules Verne
Centre Hospitalier Universitaire Amiens-Picardie
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Picardie Jules Verne
Centre Hospitalier Universitaire Amiens-Picardie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Picardie Jules Verne, Centre Hospitalier Universitaire Amiens-Picardie filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of WO2012107589A1 publication Critical patent/WO2012107589A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Definitions

  • the present invention relates to uses, methods and compositions for treating an infection by a member of the Flaviviridae family, such as HCV, in a subject in need thereof.
  • HCV is a single-stranded positive RNA virus, which belongs to the family of
  • Flaviviride genus Hepacivirus.
  • the genome of HCV comprises a single positive-stranded RNA that encodes a polyprotein of about 3010 amino acid residues, flanked at either end by noncoding regions (NCRs).
  • NCRs noncoding regions
  • the 5 '-NCR and the first part of the region encoding the polyprotein fold into a complex structure of hairpin loops and unpaired regions that can act as an internal ribosome entry site.
  • This means that translation of the virus genome is cap-independent with the initiation of translation directed to the AUG codon at the beginning of the polyprotein rather than the most 5 '-terminal AUG.
  • RNA secondary structures have also been described for the 3 '-untranslated region, and it is thought that these might play a role in the replication of the virus genome, although there is at present no direct evidence for this.
  • the N-terminus of the polyprotein is comprised of three structural proteins (core, El and E2) and release of these proteins from the polyprotein is dependent upon the signal peptidase associated with the cellular endoplasmic reticulum. Release of the six nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A and NS5B) from the remainder of the polyprotein is mediated by the virus NS2- NS3 and NS3-NS4A proteases.
  • HCV hepatitis C virus
  • Virus RNA can first be detected from 1 to 2 months after exposure, and this is usually accompanied or shortly followed by a rise in blood levels of alanine aminotransferase, a marker for liver damage. Seroconversion occurs from about 3 months after exposure, with reactivity first detected to the NS3 and core antigens. Between 20 and 50% of acutely infected individuals are able to clear virus infection, and this outcome has been correlated with the presence of specific antibody responses to the HVR of the E2 protein and to a CD4+ response to part of the NS3 protein.
  • Chronic hepatitis C can be clinically silent for many years, although there will often be intermittent elevations in serum alanine aminotransferase levels. Histological examination of liver biopsies from chronically infected individuals usually reveals some signs of liver pathology, although these are often very mild. A typical pathological feature is the presence of lymphoid follicles within the portal tracts, together with periportal inflammation and damage to the bile ducts. In the most extreme cases, the liver becomes cirrhotic with the accumulation of fibrous tissue between hepatocyte nodules eventually leading to liver failure. The extent of liver pathology generally increases with the duration of infection, albeit with a timescale of decades rather than years. Why the rate of progression to disease should vary between individuals is not fully understood.
  • Immunodeficiency can lead to a relatively rapid rate of progression, while there is conflicting evidence for an association between virus genotype and progression, perhaps because of underlying epidemiological associations between virus genotype, the age of acquisition of infection and the duration of infection.
  • HCV infection A variety of nonhepatic disorders have been associated with HCV infection, including autoimmune and lymphoproliferative disorders, chronic fatigue, essential type II mixed cryoglobulinemia, membranoproliferative glomerulonephritis and purpura cutanea tardia. Although these manifestations have been interpreted by some as evidence for extrahepatic replication of HCV, several of these conditions could also be produced indirectly as consequences of chronic liver disease or because of the accumulation of HCV in immune complexes.
  • Current therapy consists in the association of pegylated interferon (IFN) alpha and ribavirin (l-B-D-ribofuranosyl-l,2,4-triazole-3-carboxamide).
  • IFN pegylated interferon
  • ribavirin l-B-D-ribofuranosyl-l,2,4-triazole-3-carboxamide
  • HCV hepatitis C virus
  • SVR sustained virological response
  • HCV entry in hepatocytes represents a complex mechanism dependent on several environmental factors such as pH, temperature and other cellular factors.
  • the particle2 After an initial binding step involving molecules like GAGs and LDL-R facilitating initial attachment to the host cell, the particle2, through interactions with glycoproteins-El/E2 complex, interacts with SR-BI and CD81.
  • CLDN1 and OCLDN act at a later stage and probably after a lateral migration of the virus-receptor complex to the tight junctions (TJ).
  • TJ tight junctions
  • HCV is internalized by clathrin-mediated endocytosis, where fusion probably occurs in early endosomes.
  • the entry process seems far from being fully understood as some human cell lines expressing these receptors remain resistant to HCV, suggesting that one or more human- specific HCV entry factor (s) remain (s) to be discovered.
  • the present invention relates to uses, methods and compositions for treating an infection by a member of the Flaviviridae family, such as HCV, in a subject in need thereof.
  • the prevention invention relates to an agent effective to inhibit the binding of a HCV envelope glycoprotein (El or E2) to CD229 protein present on the surface of hepatocytes for use in the treatment of an HCV infection or for use in the treatment of a disease associated with an HCV infection in a subj ect in need thereof, such as acute or chronic hepatitis C or for use to prevent a subject from contracting HCV or for use in the prevention of liver diseases, such as liver fibrosis, liver cirrhosis or hepatocellular carcinoma.
  • the compound includes but is not limited to an antibody, a small molecule, and a polypeptide.
  • Another object of the invention is an inhibitor of CD229 gene expression for use in the treatment of an HCV infection or for use in the treatment of a disease associated with an HCV infection in a subject in need thereof, such as acute or chronic hepatitis C or for use to prevent a subject from contracting HCV or for use in the prevention of liver diseases, such as liver fibrosis, liver cirrhosis or hepatocellular carcinoma.
  • a disease associated with an HCV infection in a subject in need thereof such as acute or chronic hepatitis C or for use to prevent a subject from contracting HCV or for use in the prevention of liver diseases, such as liver fibrosis, liver cirrhosis or hepatocellular carcinoma.
  • the present invention also relates to a method of determining whether a compound is capable of inhibiting HCV infection of a cell which comprises the step consisting of determining whether a candidate compound is efficient to inhibit the binding of a HCV envelope glycoprotein to CD229 protein present on the surface of hepatocytes and ii) positively selecting the candidate compound that is efficient to inhibit the binding of a HCV envelope glycoprotein to CD229 protein present on the surface of hepatocytes.
  • the inventors show SLAM-CD229 gene expression on hepatocytes and its implication in HCV attachment and infection.
  • CD229 belongs to the Signaling Lymphocytic Activation Molecule (SLAM) family, which is constituted of nine cellular receptors known to be expressed on immune cells. All members of this family possess a similar structural organization, including an extracellular domain with either two or four Ig-like domains, a single transmembrane segment and an intracytoplasmic region with tyrosine-based motifs.
  • SLAM Signaling Lymphocytic Activation Molecule
  • CD229 is also known as hly9; mLY9; CD229; SLAMF3; LY9.
  • a representative amino sequence of CD229 is the sequence SEQ ID NO: l . Unlike the other members of the SLAM family, CD229 has four rather than two extracellular Ig domains.
  • Domains 1 and 3 are similar, as well as domains 2 and 4 (Engel, P., Eck, M. J., Terhorst, C. The SAP and SLAM families in immune responses and Xlinked lymphoproliferative disease. Nat Rev Immunol. 3, 813-21 (2003).; Sandrin, M. S., Henning, M. M., Lo, M. F., Baker, E., Sutherland, G. R., McKenzie, I. F. Isolation and characterization of cDNA clones for Humly9: the human homologue of mouse Ly9. Immunognetics. 43, 13-9 (1996).).
  • CD229 is known to be the only member able to be internalized by clathrin-mediated endocytosis (Del Valle, J.M., Engel, P., Martin, M. The cell surface expression of SAP- binding receptor CD229 is regulated via its interaction with clathrin-associated adaptor complex 2 (AP-2). J Biol chem. (2003).). In spite of its role in the immune system, CD229 is not well known and the exact functions of this receptor remain to be elucidated. The inventors described for the first time both the expression and functionality of CD299 in hepatocytes. The analysis of CD229 mRNA and protein sequence is similar in lymphocytes as well as hepatocytes.
  • CD229 blockade by antibodies and down-modulation by siRNA decreases HCV-hepatocytes susceptibility.
  • CD229 overexpression in human hepatoma cells Huh-7 significantly increases HCV attachment and replication.
  • the ectopic expression of CD229 confers susceptibility to HCV in resistant humhepatocytess Hep-G2 and monkey kidney cells COS-7.
  • the use of peptides mimicking each domain of CD229 shows that the first extracellular domain of CD229 is required for HCV attachment and entry.
  • CD229 novel key factor for HCV entry and a potential new target for antiviral drug development.
  • the present invention provides for uses, methods and compositions (such as pharmaceutical compositions) for treating an infection by a virus belonging to the Flaviviridae family in a subject in need thereof.
  • the member of the Flaviviridae family may be a member of the Flavivirus genus such as the Japanese encephalitis virus group, including Japanese encephalitis virus and West Nile Virus. Alternatively it may be a member of the Yellow fever virus group. Alternatively it may be a member of the Pestivirus genus, such as Bovine viral diarrhea virus (BVDV-1 and/or BVDV-2), Classical swine fever virus, Border disease virus. Alternatively, the Flaviviridae members may belong to the Hepacivirus genus such as the hepatitis G virus (HGV).
  • HGV hepatitis G virus
  • the invention provides uses, methods and compositions for treating a hepatitis C virus (HCV) infection. More specifically the present invention provides for uses, methods and compositions for treating acute or chronic C hepatitis. Even more specifically the present invention provides for uses, methods and compositions for preventing diseases associated with a Hepatitis C virus infection such as autoimmune and lymphoproliferative disorders, chronic fatigue, essential type II mixed cryoglobulinaemia, membranoproliferative glomerulonephritis and purpura cutanea tardia. The present invention also encompasses uses, methods and composition for the prevention of liver diseases, such as liver fibrosis, liver cirrhosis or hepatocellular carcinoma.
  • liver diseases such as liver fibrosis, liver cirrhosis or hepatocellular carcinoma.
  • treatment refers to inhibiting the disease or condition, i.e. arresting its development; relieving the disease or condition, i.e. causing regression of the condition; or relieving the conditions caused by the disease, i.e. symptoms of the disease.
  • prevention refers to preventing the disease or condition from occurring in a subject which has not yet been diagnosed as having it
  • the prevention invention relates to an agent effective to inhibit the binding of a favivirus envelope glycoprotein to CD229 protein present on the surface of hepatocytes for use in the treatment of a flavivirus infection or for use in the treatment of a disease associated with a flavivirus infection in a subject in need thereof.
  • the prevention invention relates to an agent effective to inhibit the binding of a HCV envelope glycoprotein (El or E2) to CD229 protein present on the surface of hepatocytes for use in the treatment of an HCV infection or for use in the treatment of a disease associated with an HCV infection in a subject in need thereof, such as acute or chronic hepatitis C or for use to prevent a subject from contracting HCV or for use in the prevention of liver diseases, such as liver fibrosis, liver cirrhosis or hepatocellular carcinoma.
  • the compound includes but is not limited to an antibody, a small molecule, and a polypeptide.
  • the agent is an antibody.
  • the invention embraces antibodies or fragments of antibodies having the ability to block the interaction between HCV and CD229.
  • the antibodies may have specificity to HCV or CD229.
  • the antibodies or fragment of antibodies are directed to all or a portion of the extracellular domain of CD229.
  • the antibodies or fragment of antibodies are directed to the extracellular region of CD229 ranging from residue at position 1 to residue at position 448 in sequence SEQ ID NO: l.
  • Even more particularly antibodies or fragments of antibodies are directed to a polypeptide comprises consecutive amino acids having a sequence which corresponds to the sequence of at least a portion of an extracellular domain of CD229, which portion binds to a HCV envelope glycoprotein.
  • the antibodies or fragment of antibodies are directed to an extracellular domain of CD229.
  • the antibodies or fragment of antibodies are directed to the extracellular domain "domain 1" of CD229 ranging from residue at position 73 to residue at position 154 in sequence SEQ ID NO : l .
  • the antibodies or fragment of antibodies are directed to the extracellular domain comprises consecutive amino acids having a sequence as set forth in SEQ ID NO: 2 (peptide PI) or SEQ ID NO:3 (peptide P2).
  • This invention also provides an antibody or portion thereof capable of inhibiting binding of CD229 to a HCV envelope glycoprotein, which antibody binds to an epitope located within a region of a HCV envelope glycoprotein, which region of a HCV envelope glycoprotein binds to CD229.
  • the antibody is a monoclonal antibody. In one embodiment of the antibodies or portions thereof described herein, the antibody is a polyclonal antibody. In one embodiment of the antibodies or portions thereof described herein, the antibody is a humanized antibody. In one embodiment of the antibodies or portions thereof described herein, the antibody is a chimeric antibody. In one embodiment of the antibodies or portions thereof described herein, the portion of the antibody comprises a light chain of the antibody. In one embodiment of the antibodies or portions thereof described herein, the portion of the antibody comprises a heavy chain of the antibody. In one embodiment of the antibodies or portions thereof described herein, the portion of the antibody comprises a Fab portion of the antibody.
  • the portion of the antibody comprises a F(ab')2 portion of the antibody. In one embodiment of the antibodies or portions thereof described herein, the portion of the antibody comprises a Fc portion of the antibody. In one embodiment of the antibodies or portions thereof described herein, the portion of the antibody comprises a Fv portion of the antibody. In one embodiment of the antibodies or portions thereof described herein, the portion of the antibody comprises a variable domain of the antibody. In one embodiment of the antibodies or portions thereof described herein, the portion of the antibody comprises one or more CDR domains of the antibody.
  • antibody includes both naturally occurring and non-naturally occurring antibodies. Specifically, “antibody” includes polyclonal and monoclonal antibodies, and monovalent and divalent fragments thereof. Furthermore, “antibody” includes chimeric antibodies, wholly synthetic antibodies, single chain antibodies, and fragments thereof. The antibody may be a human or nonhuman antibody. A nonhuman antibody may be humanized by recombinant methods to reduce its immunogenicity in man.
  • Antibodies are prepared according to conventional methodology. Monoclonal antibodies may be generated using the method of Kohler and Milstein (Nature, 256:495, 1975). To prepare monoclonal antibodies useful in the invention, a mouse or other appropriate host animal is immunized at suitable intervals (e.g., twice-weekly, weekly, twice-monthly or monthly) with antigenic forms of HCV, HCV envelope glycoproteins, or CD229. The animal may be administered a final "boost" of antigen within one week of sacrifice. It is often desirable to use an immunologic adjuvant during immunization.
  • Suitable immunologic adjuvants include Freund's complete adjuvant, Freund's incomplete adjuvant, alum, Ribi adjuvant, Hunter's Titermax, saponin adjuvants such as QS21 or Quil A, or CpG-containing immunostimulatory oligonucleotides.
  • Other suitable adjuvants are well-known in the field.
  • the animals may be immunized by subcutaneous, intraperitoneal, intramuscular, intravenous, intranasal or other routes. A given animal may be immunized with multiple forms of the antigen by multiple routes.
  • the recombinant HCV envelope glycoproteins may be provided by surface expression on recombinant cell lines.
  • CD229 may be provided in the form of human cells that express CD229. Recombinant forms of CD229 may be provided using any previously described method.
  • the antigen may be provided as synthetic peptides corresponding to antigenic regions of interest (SEQ ID NO: 2 or SEQ ID NO:3).
  • lymphocytes are isolated from the spleen, lymph node or other organ of the animal and fused with a suitable myeloma cell line using an agent such as polyethylene glycol to form a hydridoma.
  • an antibody from which the pFc' region has been enzymatically cleaved, or which has been produced without the pFc' region designated an F(ab')2 fragment, retains both of the antigen binding sites of an intact antibody.
  • an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule.
  • Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd.
  • the Fd fragments are the major determinant of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation.
  • CDRs complementarity determining regions
  • FRs framework regions
  • CDR1 through CDRS complementarity determining regions
  • compositions and methods that include humanized forms of antibodies.
  • humanized describes antibodies wherein some, most or all of the amino acids outside the CDR regions are replaced with corresponding amino acids derived from human immunoglobulin molecules.
  • Methods of humanization include, but are not limited to, those described in U.S. Pat. Nos. 4,816,567,5,225,539,5,585,089, 5,693,761, 5,693,762 and 5,859,205, which are hereby incorporated by reference.
  • the above U. S. Pat. Nos. 5,585,089 and 5,693,761 , and WO 90/07861 also propose four possible criteria which may used in designing the humanized antibodies.
  • the first proposal was that for an acceptor, use a framework from a particular human immunoglobulin that is unusually homologous to the donor immunoglobulin to be humanized, or use a consensus framework from many human antibodies.
  • the second proposal was that if an amino acid in the framework of the human immunoglobulin is unusual and the donor amino acid at that position is typical for human sequences, then the donor amino acid rather than the acceptor may be selected.
  • the third proposal was that in the positions immediately adjacent to the 3 CDRs in the humanized immunoglobulin chain, the donor amino acid rather than the acceptor amino acid may be selected.
  • the fourth proposal was to use the donor amino acid reside at the framework positions at which the amino acid is predicted to have a side chain atom within 3 A of the CDRs in a three dimensional model of the antibody and is predicted to be capable of interacting with the CDRs.
  • the above methods are merely illustrative of some of the methods that one skilled in the art could employ to make humanized antibodies.
  • One of ordinary skill in the art will be familiar with other methods for antibody humanization.
  • humanized forms of the antibodies some, most or all of the amino acids outside the CDR regions have been replaced with amino acids from human immunoglobulin molecules but where some, most or all amino acids within one or more CDR regions are unchanged. Small additions, deletions, insertions, substitutions or modifications of amino acids are permissible as long as they would not abrogate the ability of the antibody to bind a given antigen.
  • Suitable human immunoglobulin molecules would include IgGl, IgG2, IgG3, IgG4, IgA and IgM molecules.
  • a "humanized" antibody retains a similar antigenic specificity as the original antibody.
  • the affinity and/or specificity of binding of the antibody may be increased using methods of "directed evolution", as described by Wu et al, I. Mol. Biol. 294: 151, 1999, the contents of which are incorporated herein by reference.
  • Fully human monoclonal antibodies also can be prepared by immunizing mice transgenic for large portions of human immunoglobulin heavy and light chain loci. See, e.g., U.S. Pat. Nos. 5,591,669, 5,598,369, 5,545,806, 5,545,807, 6, 150,584, and references cited therein, the contents of which are incorporated herein by reference. These animals have been genetically modified such that there is a functional deletion in the production of endogenous (e.g., murine) antibodies. The animals are further modified to contain all or a portion of the human germ-line immunoglobulin gene locus such that immunization of these animals will result in the production of fully human antibodies to the antigen of interest.
  • monoclonal antibodies can be prepared according to standard hybridoma technology. These monoclonal antibodies will have human immunoglobulin amino acid sequences and therefore will not provoke human anti-mouse antibody (KAMA) responses when administered to humans.
  • KAMA human anti-mouse antibody
  • In vitro methods also exist for producing human antibodies. These include phage display technology (U.S. Pat. Nos. 5,565,332 and 5,573,905) and in vitro stimulation of human B cells (U.S. Pat. Nos. 5,229,275 and 5,567,610). The contents of these patents are incorporated herein by reference.
  • the present invention also provides for F(ab') 2 Fab, Fv and Fd fragments; chimeric antibodies in which the Fc and/or FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric F(ab')2 fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric Fab fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; and chimeric Fd fragment antibodies in which the FR and/or CDR1 and/or CDR2 regions have been replaced by homologous human or non-human sequences.
  • the present invention also includes so-called single chain antibodies.
  • the various antibody molecules and fragments may derive from any of the commonly known immunoglobulin classes, including but not limited to IgA, secretory IgA, IgE, IgG and IgM.
  • IgG subclasses are also well known to those in the art and include but are not limited to human IgGl, IgG2, IgG3 and IgG4.
  • the antibody according to the invention is a single domain antibody.
  • the term "single domain antibody” (sdAb) or "VHH” refers to the single heavy chain variable domain of antibodies of the type that can be found in Camelid mammals which are naturally devoid of light chains. Such VHH are also called “nanobody®”. According to the invention, sdAb can particularly be llama sdAb.
  • the agent is an aptamer. Aptamers are a class of molecule that represents an alternative to antibodies in term of molecular recognition. Aptamers are oligonucleotide sequences with the capacity to recognize virtually any class of target molecules with high affinity and specificity.
  • Such ligands may be isolated through Systematic Evolution of Ligands by Exponential enrichment (SELEX) of a random sequence library.
  • the random sequence library is obtainable by combinatorial chemical synthesis of DNA.
  • each member is a linear oligomer, eventually chemically modified, of a unique sequence.
  • the invention embraces aptamers having the ability to block the interaction between HCV and CD229.
  • the aptamers may have specificity to HCV or CD229.
  • the aptamers are directed to all or a portion of the extracellular domain of CD229.
  • the aptamers are directed to the extracellular region of CD229 ranging from residue at position 1 to residue at position 448 in sequence SEQ ID NO: l .
  • aptamers are directed to a polypeptide comprises consecutive amino acids having a sequence which corresponds to the sequence of at least a portion of an extracellular domain of CD229, which portion binds to a HCV envelope glycoprotein.
  • the aptamers are directed to an extracellular domain of CD229.
  • the aptamers are directed to the extracellular domain "domain 1" of CD229 ranging from residue at position 73 to residue at position 154 in sequence SEQ ID NO: l .
  • the aptamers are directed to the extracellular domain comprises consecutive amino acids having a sequence as set forth in SEQ ID NO: 2 (peptide PI) or SEQ ID NO: 3 (peptide P2).
  • This invention also provides an aptamer capable of inhibiting binding of CD229 to a HCV envelope glycoprotein, which aptamer binds to an epitope located within a region of a HCV envelope glycoprotein, which region of a HCV envelope glycoprotein binds to CD229.
  • the agent is a polypeptide.
  • the polypeptide is a functional equivalent of CD229.
  • a “functional equivalent of CD229 is a compound which is capable of binding to HCV, thereby preventing its interaction with CD229.
  • the term “functional equivalent” includes fragments, mutants, and muteins of CD229.
  • the term “functionally equivalent” thus includes any equivalent of CD229 obtained by altering the amino acid sequence, for example by one or more amino acid deletions, substitutions or additions such that the protein analogue retains the ability to bind to HCV, preferably the envelope of HCV. Amino acid substitutions may be made, for example, by point mutation of the DNA encoding the amino acid sequence.
  • Functional equivalents include molecules that bind HCV, preferably a HCV envelope glycoproteins, and comprise all or a portion of the extracellular domains of CD229.
  • the functional equivalents include soluble forms of the CD229 proteins.
  • a suitable soluble form of these proteins, or functional equivalents thereof, might comprise, for example, a truncated form of the protein from which the transmembrane domain has been removed by chemical, proteolytic or recombinant methods.
  • the functional equivalent comprises all or a portion of the extracellular domain of CD229.
  • the extracellular region of CD229 ranges from residue at position 1 to residue at position 448 in sequence SEQ ID NO: l .
  • the functional equivalent comprises all or a portion of the extracellular domain "domain 1" of CD229 ranging from residue at position 73 to residue at position 154 in sequence SEQ ID NO: l .
  • the functional equivalent is at least 80% homologous to the corresponding protein.
  • the functional equivalent is at least 90% homologous as assessed by any conventional analysis algorithm such as for example, the Pileup sequence analysis software (Program Manual for the Wisconsin Package, 1996)..
  • a functionally equivalent fragment as used herein also may mean any fragment or assembly of fragments of CD229 that binds to HCV, preferably that binds to a HCV envelope glycoproteins.
  • the present invention provides a polypeptide capable of inhibiting binding of CD229 to a HCV envelope glycoprotein, which polypeptide comprises consecutive amino acids having a sequence which corresponds to the sequence of at least a portion of an extracellular domain of CD229, which portion binds to a HCV envelope glycoprotein.
  • the polypeptide corresponds to an extracellular domain of CD229.
  • the extracellular domain comprises consecutive amino acids having a sequence as set forth in SEQ ID NO:2 or SEQ ID NO:3.
  • Functionally equivalent fragments may belong to the same protein family as the human CD229 proteins identified herein.
  • protein family is meant a group of proteins that share a common function and exhibit common sequence homology.
  • homology between functionally equivalent protein sequences is at least 25% across the whole of amino acid sequence of the complete protein. More preferably, the homology is at least 50%, even more preferably 75% across the whole of amino acid sequence of the protein or protein fragment. More preferably, homology is greater than 80% across the whole of the sequence. More preferably, homology is greater than 90% across the whole of the sequence. More preferably, homology is greater than 95% across the whole of the sequence.
  • binding specifically means that the functionally equivalent analogue has high affinity for HCV or a HCV envelope glycoproteins but not for control proteins. Specific binding may be measured by a number of techniques such as ELISA, flow cytometry, western blotting, or immunoprecipitation. Preferably, the functionally equivalent analogue specifically binds to HCV or a HCV envelope glycoproteins at nanomolar or picomolar concentrations.
  • the Polypeptides of the invention may be produced by any suitable means, as will be apparent to those of skill in the art.
  • expression may conveniently be achieved by culturing under appropriate conditions recombinant host cells containing the polypeptide of the invention.
  • the polypeptide is produced by recombinant means, by expression from an encoding nucleic acid molecule.
  • Systems for cloning and expression of a polypeptide in a variety of different host cells are well known.
  • the polypeptide When expressed in recombinant form, the polypeptide is preferably generated by expression from an encoding nucleic acid in a host cell.
  • a host cell Any host cell may be used, depending upon the individual requirements of a particular system. Suitable host cells include bacteria mammalian cells, plant cells, yeast and baculovirus systems. Mammalian cell lines available in the art for expression of a heterologous polypeptide include Chinese hamster ovary cells. HeLa cells, baby hamster kidney cells and many others. Bacteria are also preferred hosts for the production of recombinant protein, due to the ease with which bacteria may be manipulated and grown. A common, preferred bacterial host is E coli.
  • polypeptides used in the therapeutic methods of the present invention may be modified in order to improve their therapeutic efficacy.
  • modification of therapeutic compounds may be used to decrease toxicity, increase circulatory time, or modify biodistribution.
  • the toxicity of potentially important therapeutic compounds can be decreased significantly by combination with a variety of drug carrier vehicles that modify biodistribution.
  • adding dipeptides can improve the penetration of a circulating agent in the eye through the blood retinal barrier by using endogenous transporters.
  • a strategy for improving drug viability is the utilization of water-soluble polymers.
  • water-soluble polymers have been shown to modify biodistribution, improve the mode of cellular uptake, change the permeability through physiological barriers; and modify the rate of clearance from the body.
  • water-soluble polymers have been synthesized that contain drug moieties as terminal groups, as part of the backbone, or as pendent groups on the polymer chain.
  • PEG Polyethylene glycol
  • Attachment to various drugs, proteins, and liposomes has been shown to improve residence time and decrease toxicity.
  • PEG can be coupled to active agents through the hydroxyl groups at the ends of the chain and via other chemical methods; however, PEG itself is limited to at most two active agents per molecule.
  • copolymers of PEG and amino acids were explored as novel biomaterials which would retain the biocompatibility properties of PEG, but which would have the added advantage of numerous attachment points per molecule (providing greater drug loading), and which could be synthetically designed to suit a variety of applications.
  • PEGylation techniques for the effective modification of drugs.
  • drug delivery polymers that consist of alternating polymers of PEG and tri-functional monomers such as lysine have been used by VectraMed (Plainsboro, N.J.).
  • the PEG chains typically 2000 daltons or less
  • Such copolymers retain the desirable properties of PEG, while providing reactive pendent groups (the carboxylic acid groups of lysine) at strictly controlled and predetermined intervals along the polymer chain.
  • the reactive pendent groups can be used for derivatization, cross-linking, or conjugation with other molecules.
  • These polymers are useful in producing stable, long-circulating pro-drugs by varying the molecular weight of the polymer, the molecular weight of the PEG segments, and the cleavable linkage between the drug and the polymer.
  • the molecular weight of the PEG segments affects the spacing of the drug/linking group complex and the amount of drug per molecular weight of conjugate (smaller PEG segments provides greater drug loading).
  • increasing the overall molecular weight of the block co-polymer conjugate will increase the circulatory half-life of the conjugate. Nevertheless, the conjugate must either be readily degradable or have a molecular weight below the threshold-limiting glomular filtration (e.g., less than 45 kDa).
  • linkers may be used to maintain the therapeutic agent in a pro-drug form until released from the backbone polymer by a specific trigger, typically enzyme activity in the targeted tissue.
  • a specific trigger typically enzyme activity in the targeted tissue.
  • this type of tissue activated drug delivery is particularly useful where delivery to a specific site of biodistribution is required and the therapeutic agent is released at or near the site of pathology.
  • Linking group libraries for use in activated drug delivery are known to those of skill in the art and may be based on enzyme kinetics, prevalence of active enzyme, and cleavage specificity of the selected disease-specific enzymes.
  • Such linkers may be used in modifying the protein or fragment of the protein described herein for therapeutic delivery.
  • Another object of the invention is an inhibitor of CD229 gene expression for use in the treatment of a flavivirus infection in a subject in need thereof.
  • Another object of the invention is an inhibitor of CD229 gene expression for use in the treatment of an HCV infection or for use in the treatment of a disease associated with an HCV infection in a subject in need thereof, such as acute or chronic hepatitis C or for use to prevent a subject from contracting HCV or for use in the prevention of liver diseases, such as liver fibrosis, liver cirrhosis or hepatocellular carcinoma.
  • a disease associated with an HCV infection in a subject in need thereof such as acute or chronic hepatitis C or for use to prevent a subject from contracting HCV or for use in the prevention of liver diseases, such as liver fibrosis, liver cirrhosis or hepatocellular carcinoma.
  • an “inhibitor of expression” refers to a natural or synthetic compound that has a biological effect to inhibit the expression of a gene. Therefore, an “inhibitor of CD229 gene expression” denotes a natural or synthetic compound that has a biological effect to inhibit the expression of CD229 gene.
  • said inhibitor of CD229 gene expression is a siRNA, an antisense oligonucleotide or a ribozyme.
  • Inhibitors of CD229 gene expression for use in the present invention may be based on antisense oligonucleotide constructs.
  • Anti-sense oligonucleotides including anti-sense RNA molecules and anti-sense DNA molecules, would act to directly block the translation of CD229 mRNA by binding thereto and thus preventing protein translation or increasing mRNA degradation, thus decreasing the level of CD229 proteins, and thus activity, in a cell.
  • antisense oligonucleotides of at least about 15 bases and complementary to unique regions of the mRNA transcript sequence encoding CD229 can be synthesized, e.g., by conventional phosphodiester techniques and administered by e.g., intravenous injection or infusion.
  • Small inhibitory RNAs can also function as inhibitors of CD229 gene expression for use in the present invention.
  • CD229 gene expression can be reduced by contacting the tumor, subject or cell with a small double stranded RNA (dsRNA), or a vector or construct causing the production of a small double stranded RNA, such that CD229 gene expression is specifically inhibited (i.e. RNA interference or RNAi).
  • dsRNA small double stranded RNA
  • RNAi RNA interference
  • Methods for selecting an appropriate dsRNA or dsRNA-encoding vector are well known in the art for genes whose sequence is known (e.g. see Tuschi, T. et al. (1999); Elbashir, S. M. et al. (2001); Hannon, GJ.
  • siRNA according to the invention may those described in the EXAMPLE (SEQ ID NO:5-7).
  • Ribozymes can also function as inhibitors of CD229 gene expression for use in the present invention.
  • Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA.
  • the mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage.
  • Engineered hairpin or hammerhead motif ribozyme molecules that specifically and efficiently catalyze endonucleolytic cleavage of CD229 mRNA sequences are thereby useful within the scope of the present invention.
  • ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, which typically include the following sequences, GUA, GUU, and GUC. Once identified, short RNA sequences of between about 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site can be evaluated for predicted structural features, such as secondary structure, that can render the oligonucleotide sequence unsuitable. The suitability of candidate targets can also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides, using, e.g., ribonuclease protection assays.
  • antisense oligonucleotides and ribozymes useful as inhibitors of CD229 gene expression can be prepared by known methods. These include techniques for chemical synthesis such as, e.g., by solid phase phosphoramadite chemical synthesis. Alternatively, anti-sense RNA molecules can be generated by in vitro or in vivo transcription of DNA sequences encoding the RNA molecule. Such DNA sequences can be incorporated into a wide variety of vectors that incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. Various modifications to the oligonucleotides of the invention can be introduced as a means of increasing intracellular stability and half-life.
  • Possible modifications include but are not limited to the addition of flanking sequences of ribonucleotides or deoxyribonucleotides to the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2'-0-methyl rather than phosphodiesterase linkages within the oligonucleotide backbone.
  • Antisense oligonucleotides siRNAs and ribozymes of the invention may be delivered in vivo alone or in association with a vector.
  • a "vector" is any vehicle capable of facilitating the transfer of the antisense oligonucleotide siRNA or ribozyme nucleic acid to the cells and preferably cells expressing CD229.
  • the vector transports the nucleic acid to cells with reduced degradation relative to the extent of degradation that would result in the absence of the vector.
  • the vectors useful in the invention include, but are not limited to, plasmids, phagemids, viruses, other vehicles derived from viral or bacterial sources that have been manipulated by the insertion or incorporation of the the antisense oligonucleotide siRNA or ribozyme nucleic acid sequences.
  • Viral vectors are a preferred type of vector and include, but are not limited to nucleic acid sequences from the following viruses: retrovirus, such as moloney murine leukemia virus, harvey murine sarcoma virus, murine mammary tumor virus, and rouse sarcoma virus; adenovirus, adeno-associated virus; SV40-type viruses; polyoma viruses; Epstein-Barr viruses; papilloma viruses; herpes virus; vaccinia virus; polio virus; and RNA virus such as a retrovirus.
  • retrovirus such as moloney murine leukemia virus, harvey murine sarcoma virus, murine mammary tumor virus, and rouse sarcoma virus
  • retrovirus such as moloney murine leukemia virus, harvey murine sarcoma virus, murine mammary tumor virus, and rouse sarcoma virus
  • adenovirus adeno
  • Non-cytopathic viruses include retroviruses (e.g., lentivirus), the life cycle of which involves reverse transcription of genomic viral RNA into DNA with subsequent proviral integration into host cellular DNA. Retroviruses have been approved for human gene therapy trials. Most useful are those retroviruses that are replication-deficient (i.e., capable of directing synthesis of the desired proteins, but incapable of manufacturing an infectious particle). Such genetically altered retroviral expression vectors have general utility for the high-efficiency transduction of genes in vivo.
  • adeno-viruses and adeno-associated viruses are double-stranded DNA viruses that have already been approved for human use in gene therapy.
  • the adeno-associated virus can be engineered to be replication deficient and is capable of infecting a wide range of cell types and species. It further has advantages such as, heat and lipid solvent stability; high transduction frequencies in cells of diverse lineages, including hemopoietic cells; and lack of superinfection inhibition thus allowing multiple series of transductions.
  • the adeno-associated virus can integrate into human cellular DNA in a site-specific manner, thereby minimizing the possibility of insertional mutagenesis and variability of inserted gene expression characteristic of retroviral infection.
  • adeno-associated virus infections have been followed in tissue culture for greater than 100 passages in the absence of selective pressure, implying that the adeno-associated virus genomic integration is a relatively stable event.
  • the adeno- associated virus can also function in an extrachromosomal fashion.
  • Plasmid vectors have been extensively described in the art and are well known to those of skill in the art. See e.g., SANBROOK et al, "Molecular Cloning: A Laboratory Manual," Second Edition, Cold Spring Harbor Laboratory Press, 1989. In the last few years, plasmid vectors have been used as DNA vaccines for delivering antigen-encoding genes to cells in vivo. They are particularly advantageous for this because they do not have the same safety concerns as with many of the viral vectors. These plasmids, however, having a promoter compatible with the host cell, can express a peptide from a gene operatively encoded within the plasmid.
  • Plasmids may be delivered by a variety of parenteral, mucosal and topical routes.
  • the DNA plasmid can be injected by intramuscular, intradermal, subcutaneous, or other routes. It may also be administered by intranasal sprays or drops, rectal suppository and orally.
  • the plasmids may be given in an aqueous solution, dried onto gold particles or in association with another DNA delivery system including but not limited to liposomes, dendrimers, cochleate and microencapsulation.
  • Another object of the invention relates to a method for use in the treatment of an HCV infection or a disease associated with an HCV infection, such as acute or chronic hepatitis C or for the prevention of liver diseases, such as liver fibrosis, liver cirrhosis or hepatocellular carcinoma comprising the administration of a therapeutically effective amount of at least one agent effective to inhibit the binding of a HCV envelope glycoprotein to CD229 protein present on the surface of hepatocytes or inhibitor of CD229 gene expression to a subject in need thereof.
  • a "therapeutically effective amount" of the agent effective to inhibit the binding of a HCV envelope glycoprotein to CD229 protein present on the surface of hepatocytes or inhibitor of CD229 gene expression as above described is meant a sufficient amount of the agent effective to inhibit the binding of a HCV envelope glycoprotein to CD229 protein present on the surface of hepatocytes or inhibitor of CD229 gene expression to treat a hepatitis C virus infection at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed, the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidential with the specific polypeptide employed; and like factors well known in the medical arts.
  • the daily dosage of the products may be varied over a wide range from 0.01 to 1,000 mg per adult per day.
  • the compositions contain 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 250 and 500 mg of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
  • a medicament typically contains from about 0.01 mg to about 500 mg of the active ingredient, preferably from 1 mg to about 100 mg of the active ingredient.
  • An effective amount of the drug is ordinarily supplied at a dosage level from 0.0002 mg/kg to about 20 mg/kg of body weight per day, especially from about 0.001 mg/kg to 7 mg/kg of body weight per day.
  • the agent effective to inhibit the binding of a HCV envelope glycoprotein to CD229 protein present on the surface of hepatocytes is use in combination with an agent effective to inhibit the binding of a HCV envelope glycoprotein to CD81 protein present on the surface of hepatocytes.
  • CD81 as used herein means the human CD81 protein as defined by the protein sequence listed in the SWISSPROT database (Accession No. P18582) or the EMBLIGENB ANK database (Accession No. M33690). CD81 has been shown to be involved in the entry of HCV in hepatocytes and the inventors demonstrates that the combination of such agents could synergize to inhibit the entry of HCV in hepatocytes.
  • the agent may be an antibody, a small organic molecules or a polypeptide.
  • the agent may be a functional equivalent of CD81.
  • a functional equivalent of CD81 is a compound which is capable of binding to HCV, preferably to the E2 envelope glycoprotein of HCV.
  • the term "functional equivalent” thus includes an analogue of CD81, a fragment of CD81, and CD81 mutants and muteins.
  • One region of the human CD81 protein that is shown herein to be involved in binding to the E2 protein of HCV is the EC2" region comprising amino acids 113-201 of the full length human sequence of CD81.
  • the invention encompasses proteins and protein fragments containing this region of human CD81, or containing functional equivalents of this region.
  • the functional equivalent is at least 80% homologous to the human CD81 sequence across the EC2 region of the protein, preferably at least 90% homologous as assessed by any conventional analysis algorithm such as for example, the Pileup sequence analysis software (Program Manual for the Wisconsin Package, 1996).
  • Agent effective to inhibit the binding of a HCV envelope glycoprotein to CD81 protein present on the surface of hepatocytes are well known in the art.
  • Examples of functional equivalent of CD81 are described in US 2004/0258694.
  • Example of small organiscmolecules that are agents effective to inhibit the binding of a HCV envelope glycoprotein to CD81 protein present on the surface of hepatocytes are described ins US 2003/0219893 and JP2009215280.
  • Examples of antibodies that are agents effective to inhibit the binding of a HCV envelope glycoprotein to CD81 protein present on the surface of hepatocytes are described; WO2010043650.
  • the invention relates to the use of an agent effective to inhibit the binding of a HCV envelope glycoprotein to CD229 protein present on the surface of a hepatocyte or inhibitor of CD229 gene expression as described above for use in the treatment of a subject undergoing a treatment with interferon-alpha.
  • methods of the invention further comprises administering to the subject an effective amount of interferon alpha (IFN-alpha).
  • IFN-alpha interferon alpha
  • IFN-alpha any known IFN-alpha can be used in the instant invention.
  • IFN-alpha or "IFN-alpha” as used herein refers to a family of related polypeptides that inhibit viral replication and cellular proliferation and modulate immune response.
  • IFN- alpha includes naturally occurring IFN-alpha; synthetic IFN-alpha ; derivatized IFN-alpha (e. g. , PEGylated IFN-alpha, glycosylated IFN-alpha, and the like); and analogs of naturally occurring or synthetic IFN-alpha ; essentially any IFN-alpha that has antiviral properties, as described for naturally occurring IFN-alpha.
  • Suitable interferons alpha include, but are not limited to, naturally-occurring IFN-alpha (including, but not limited to, naturally occurring IFN-alpha2a, IFN-alpha2b) ; recombinant interferon alpha-2b such as Intron-A interferon available from Schering Corporation, Kenilworth, N. J. ; recombinant interferon alpha-2a such as Roferon interferon available from Hoffmann-La Roche, Nutley, N. J. ; recombinant interferon alpha-2C such as Berofor alpha 2 interferon available from Boehringer Ingelheim Pharmaceutical, Inc.
  • naturally-occurring IFN-alpha including, but not limited to, naturally occurring IFN-alpha2a, IFN-alpha2b
  • recombinant interferon alpha-2b such as Intron-A interferon available from Schering Corporation, Kenilworth, N. J.
  • recombinant interferon alpha-2a such as Ro
  • interferon alpha- nl a purified blend of natural interferon alphas such as Sumiferon available from Sumitomo, Japan or as Wellferon interferon alpha-nl (INS) available from the Glaxo-Wellcome Ltd., London, Great Britain; and interferon alpha-n3 a mixture of natural interferon alphas made by Interferon Sciences and available from the Purdue Frederick Co. , Norwalk, Conn. , under the Alferon Tradename.
  • interferon alpha- nl a purified blend of natural interferon alphas such as Sumiferon available from Sumitomo, Japan or as Wellferon interferon alpha-nl (INS) available from the Glaxo-Wellcome Ltd., London, Great Britain
  • interferon alpha-n3 a mixture of natural interferon alphas made by Interferon Sciences and available from the Purdue Frederick Co. , Norwalk, Conn. , under the Alferon Tradename.
  • IFN-alpha also encompasses derivatives of IFN-alpha that are derivatized (e. g. , are chemically modified) to alter certain properties such as serum half-life.
  • IFN-alpha includes glycosylated IFN-alpha ; IFN-alpha derivatized with polyethylene glycol ("PEGylated IFN-alpha”); and the like. PEGylated IFN-alpha, and methods for making same, is discussed in, e. g., U. S. Patent Nos. 5,382, 657; 5,981, 709; and 5,951, 974.
  • PEGylated IFN-alpha encompasses conjugates of PEG and any of the above- described IFN-alpha molecules, including, but not limited to, PEG conjugated to interferon alpha-2a (Roferon,Hoffman La-Roche, Nutley, N. J.), interferon alpha 2b (Intron, Schering- Plough, Madison, N. J. ), interferon alpha-2c (Berofor Alpha, Boehringer Ingelheim, Ingelheim, Germany); and consensus interferon as defined by determination of a consensus sequence of naturally occurring interferons alpha (Infergen (InterMune, Inc. , Brisbane,Calif).
  • interferon alpha-2a Roferon,Hoffman La-Roche, Nutley, N. J.
  • interferon alpha 2b Intron, Schering- Plough, Madison, N. J.
  • interferon alpha-2c Boehringer Ingelheim, Ingelheim, Germany
  • consensus interferon as defined by determination of a
  • the invention relates to the use of an agent effective to inhibit the binding of a HCV envelope glycoprotein to CD229 protein present on the surface of hepatocytes or inhibitor of CD229 gene expression as described above for use in the treatment of a subject undergoing a treatment with a nucleoside analog.
  • methods of the invention further comprises administering to the subject an effective amount of a nucleoside analog for achieving a sustained viral response.
  • Said nucleoside analog may be ribavirin or derivatives thereof.
  • Ribavirin (l-B-D-ribofuranosyl-l,2,4-triazole-3-carboxamide), is a nucleoside analog available from ICN Pharmaceuticals, Inc. , Costa Mesa,Calif, and is described in the Merck Index, compound No. 8199, Eleventh Edition. Its manufacture and formulation is described in U. S. Pat. No. 4,211, 771.
  • the invention also contemplates use of derivatives of ribavirin as those described in US patent 6,277, 830, or International Patent Application WO2006067606.
  • Other derivatives include Levovirin which is the L-enantiomer of ribavirin, or Viramidine which is a 3- carboxamidine derivative of ribavirin.
  • the invention relates to the use of an agent effective to inhibit the binding of a HCV envelope glycoprotein to CD229 protein present on the surface of hepatocytes or inhibitor of CD229 gene expression as described above for use in the treatment of a subject undergoing a treatment with interferon-alpha and a nucleoside analog.
  • methods of the invention further comprises administering an effective amount of interferon alpha (IFN-alpha) and a nucleoside analog as those above described.
  • IFN-alpha interferon alpha
  • nucleoside analog as those above described.
  • the invention relates to the use of an agent effective to inhibit the binding of a HCV envelope glycoprotein to CD229 protein present on the surface of hepatocytes or inhibitor of CD229 gene expression as described above for use in the treatment of a subject undergoing a treatment with an inhibitor of HCV proteases and/or polymerases.
  • methods of the invention further comprises administering to the subject an effective amount of an inhibitor of HCV polymerases.
  • inhibitors include, but are not limited to a compound as disclosed in U. S. Patent No. 6,479, 508; a compound as disclosed in any of International Patent Application WO03010140; WO03007945, WO03010141, WO0147883, a dinucleotide analog as disclosed in Zhong et al.
  • methods of the invention further comprises administering to the subject an effective amount of an inhibitor of HCV proteases.
  • Inhibitors of NS3 protease include, but are not limited to, a compound as disclosed in Internationa Patent Applications WO03066103 WO2004103996 or WO2004093915.
  • HCV NS3 protease inhibitor peptide analogs include any compound disclosed in Patent Applications GB 2,337,262; JP10298151 ; JP 11126861; JP 11292840; JP 2001-103993; U.S. Pat. No. 6, 159,938; U.S. Pat. No.
  • Inhibitors of HCV NS3 protease have been also described in WO 03/064456, WO 03/064416 , WO 02/060926, WO 03/053349, WO 03/099316, WO 03/099274, WO 2004/032827, and. WO 2004/043339.
  • Acyl sulfamide inhibitors of the HCV NS3 protease have also been described in WO 2005/046712 or WO2006000085.
  • Inhibitors of NS3-NS4A protease are described in Patent Applications WO2005007681 WO2005035525 or WO2005028502.
  • methods of the invention further comprises administering to the subject an effective amount of a statin compound.
  • Statins which are 3-hydroxy-3- methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors may be potentially useful as anti-HCV reagents (Ikeda M. et al. 2006, Kapadia SB. et al. 2005, Ye J. et al. 2003).
  • the invention relates to the use of an agent effective to inhibit the binding of a HCV envelope glycoprotein to CD229 protein present on the surface of hepatocytes or inhibitor of CD229 gene expression as described above for use in the treatment of a subject undergoing a treatment with interferon-alpha, a nucleoside analog and an inhibitor of HCV proteases and/or polymerases.
  • kits for use in the treatment of an infection by members of the Flaviviridae family or for use in the treatment of an HCV infection or for use in the treatment of a disease associated with an HCV infection comprising a medicament comprising an agent effective to inhibit the binding of a HCV envelope glycoprotein to CD229 protein present on the surface of hepatocytes or inhibitor of CD229 gene expression expression and at least a medicament selected from the group consisting of a medicament comprising interferon-alpha, a medicament comprising a nucleoside analog and a medicament comprising an inhibitor of HCV proteases and/or polymerases or medicament comprising an agent effective to inhibit the binding of a HCV envelope glycoprotein to CD81 protein present on the surface of hepatocytes.
  • the agent effective to inhibit the binding of a HCV envelope glycoprotein to CD229 protein present on the surface of hepatocytes or inhibitor of CD229 gene expression of the invention may be combined with pharmaceutically acceptable excipients, and optionally sustained-release matrices, such as biodegradable polymers, to form therapeutic compositions.
  • “Pharmaceutically” or “pharmaceutically acceptable” refers to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to a mammal, especially a human, as appropriate.
  • a pharmaceutically acceptable carrier or excipient refers to a non-toxic solid, semi- solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
  • the active principle alone or in combination with another active principle, can be administered in a unit administration form, as a mixture with conventional pharmaceutical supports, to animals and human beings.
  • Suitable unit administration forms comprise oral-route forms such as tablets, gel capsules, powders, granules and oral suspensions or solutions, sublingual and buccal administration forms, aerosols, implants, subcutaneous, transdermal, topical, intraperitoneal, intramuscular, intravenous, subdermal, transdermal, intrathecal and intranasal administration forms and rectal administration forms.
  • the pharmaceutical compositions contain vehi cles whi ch are pharmaceutically acceptable for a formulation capable of being injected.
  • vehi cles whi ch are pharmaceutically acceptable for a formulation capable of being injected.
  • These may be in particular isotonic, sterile, saline solutions (monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride and the like or mixtures of such salts), or dry, especially freeze-dried compositions which upon addition, depending on the case, of sterilized water or physiological saline, permit the constitution of injectable solutions.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil or aqueous propylene glycol ; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
  • Solutions comprising compounds of the invention as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the agent effective to inhibit the binding of a HCV envelope glycoprotein to CD229 protein present on the surface of hepatocytes or inhibitor of CD229 gene expression of the invention can be formulated into a composition in a neutral or salt form.
  • Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like.
  • Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.
  • inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.
  • the carrier can also be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetables oils.
  • the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars or sodium chloride.
  • Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and gelatin.
  • Sterile injectable solutions are prepared by incorporating the active polypeptides in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • solutions Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective.
  • the formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, but drug release capsules and the like can also be employed.
  • aqueous solutions For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
  • sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure.
  • one dosage could be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion. Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.
  • the agent effective to inhibit the binding of a HCV envelope glycoprotein to CD229 protein present on the surface of hepatocytes or inhibitor of CD229 gene expression of the invention may be formulated within a therapeutic mixture to comprise about 0.0001 to 1.0 milligrams, or about 0.001 to 0.1 milligrams, or about 0.1 to 1.0 or even about 10 milligrams per dose or so. Multiple doses can also be administered.
  • parenteral administration such as intravenous or intramuscular injection
  • other pharmaceutically acceptable forms include, e.g. tablets or other solids for oral administration; liposomal formulations ; time release capsules ; and any other form currently used.
  • the present invention also relates to a method of determining whether a compound is capable of inhibiting HCV infection of a cell which comprises the step consisting of determining whether a candidate compound is efficient to inhibit the binding of a HCV envelope glycoprotein to CD229 protein present on the surface of hepatocytes and ii) positively selecting the candidate compound that is efficient to inhibit the binding of a HCV envelope glycoprotein to CD229 protein present on the surface of hepatocytes.
  • the method comprises the step consisting of:
  • the method comprises the step consisting of:
  • step (f) comparing the amount of CD229 protein bound to a HCV envelope glycoprotein in step (e) with the amount measured in step (c), wherein a reduced amount measured in step (e) indicates that the compound binds to a HCV envelope glycoprotein, so as to thereby determine that the compound is one which is capable of inhibiting HCV infection of the cell.
  • the method comprises the step consisting of:
  • a reduced amount of CD229 protein measured in presence of the compound indicates that the compound binds to a HCV envelope glycoprotein or CD229 protein so as to thereby determine that the compound is one which is capable of inhibiting HCV infection of the cell.
  • an entity may be made detectable by labeling it with a detectable marker.
  • the detectable CD229 protein is labeled with a detectable marker.
  • the detectable HCV envelope glycoprotein glycoprotein is labeled with a detectable marker.
  • detectable markers include but are not limited to a radioactive, calorimetric, luminescent and fluorescent markers.
  • the solid support is a microtiter plate well. In another embodiment, the solid support is a bead. In a further embodiment, the solid support is a surface plasmon resonance sensor chip.
  • the surface plasmon resonance sensor chip can have pre-immobilized streptavidin. In one embodiment, the surface plasmon resonance sensor chip is a BIAcoreTM chip.
  • the detectable molecule is labeled with a detectable marker.
  • the detectable molecule is detected by contacting it with another compound which is both capable of binding the detectable molecule and is detectable.
  • the detectable markers include those described above.
  • the term "candidate compound” includes both protein and non-protein moieties.
  • the candidate compound is a small molecule.
  • the candidate compound is a protein.
  • the protein may be, by way of example, an antibody directed against a portion of an HCV envelope glycoprotein.
  • the candidate compound may be derived from a library of low molecular weight compounds or a library of extracts from plants or other organisms.
  • the agent is known.
  • the candidate compound is not previously known.
  • the agents/compounds of the subject invention include but are not limited to compounds or molecular entities such as peptides, polypeptides, and other organic or inorganic molecules and combinations thereof. The invention will be further illustrated by the following figures and examples. However, these examples and figures should not be interpreted in any way as limiting the scope of the present invention.
  • FIGURES are a diagrammatic representation of FIGURES.
  • FIG. 1 The first extracellular domain of CD229 is involved in HCVcc attachment and entry.
  • Huh-7 cells (a) and HHPH (b) were treated with antibodies prior to HCVcc infection as described in Methods.
  • c The diagram shows CD229 topology and matched CD229 peptides.
  • CD229 and irrelevant peptides were incubated with HCVcc prior to Huh-7 cells infection (d, f) or HHPH (e) as described in Methods.
  • Viral-cell attachment was evaluated 4 h p.i. (d, e), and cell-associated viral RNA was quantified at 72h p.i.
  • HCVcc Cell culture grown HCV
  • the HCV strain J6/JFH virus was generated as previously described n. Briefly, RNA was transcribed in vitro from full-length genomes using the Megascript T7 kit (Ambion, USA) and electroporated into Huh-7 cells. HCVcc was collected from supernatants 72 h after transfection. High-titre stocks were generated by serial passage through naive Huh-7 cells.
  • Hepatic CD229 blockade Huh-7 and HHPC were treated with monoclonal antibody directed against CD81 (JS-81), or CD229 (3H or ZY) and IgGl isotype-control (5 ⁇ g/mL) for 1 h prior to addition HCVcc for 72 h. Peptides derived from CD229 were used in order to check which CD229 domains are required for HCV entry. HCVcc was incubated with peptides (0.25 ⁇ ) for lh and the mix was then added to Huh-7 for 3 h. After washes in PBS I X, cell s were either lysed for virus-cell attachment analysis or incubated during supplementary 72 h.
  • Viral RNA was extracted using the RNeasy Qiagen Kit following customers instructions (Qiagen). In some experiments, the collected supernatants were used to infect naive Huh-7 during 72 h. For viral load quantification, viral RNA from supernatants was extracted with the QiAmp®Viral RNA Kit (Qiagen). Viral RNA quantification was performed by the 7900 HT Sequence Detection System, with the TaqMan Gene Expression protocol (Applied Biosystems). GAPDH was used to normalize the quantified viral mRNA.
  • CD229 down-modulation by siRNA To knock down CD229 gene expression in Huh-7, three specific siRNA were predesigned by Ambion®. The following siRNA were used: ID114219 (Ly9-1): 5'-CCAAGUGGAGUUACUCCCUtt-3'(SEQ ID NO:5), ID212885 (Ly9-2): 5 '-CGUCCCAAAGAAAAUGUAAtt-3 ' (SEQ ID NO:6) , ID106775 (Ly9-3): 5 '- GGAAUUCACCCUGUUCGUCtt-3' (SEQ ID NO:7).
  • siRNA were introduced in Huh-7 cells using the Silencer® siRNA Transfection II Kit (Applied Biosystems, Ambion®) according to the manufacture's instructions. Briefly, 2 xl05 cells were seeded in 6-well plates and were incubated with siRNA (60 nM) in the presence of NeoFX solution (5 pL) in 100 ⁇ ⁇ of final reaction volume in OptiMEM medium, for 50 h at 37 °C.
  • the kit includes positive and negative siRNA controls.
  • the positive siRNA control targeted the GAPDH gene and the negative control siRNA was a scrambled sequence that bears no homology to the human, mouse, or rat genomes.
  • CD229 mRNA was analyzed before and after transfection. The siRNA effect on protein expression was evaluated by Western Blot and flow cytometry using a monoclonal anti-CD229.
  • CD229 over-expression CD229 from Huh-7 was cloned in pBud vector.
  • the cloned CD229 in pCIneo (a gift from Pablo Engel, Barcelona, Spain) was used in some experiments.
  • the primers used for PCR were: forward 5 ' -GATC ATC ATGGTGGC ACC AAAGAGTC AC A-3 ' (SEQ ID NO : 8) and reverse 5 '- GCAGC AGCTGCTTTTCCTTTCAGGTGAA-3 ' ( S EQ ID NO : 9 ).
  • PCR products were cloned using the Topo TA cloning (Invitrogen Life Technologies), sequenced and subcloned into the pBud CE4.1 vector using the Kpn-1 and Xho-1 sites.
  • Topo TA cloning Invitrogen Life Technologies
  • PCR products were cloned using the Topo TA cloning (Invitrogen Life Technologies), sequenced and subcloned into the pBud CE4.1 vector using the Kpn-1 and Xho-1 sites.
  • Huh-7 Huh-7
  • Hep-G2 and COS-7 cells (0.3 x 106) were seeded into 6-well dishes and 24h later were transfected with 0.8 ⁇ g of DNA using the FuGENE HD Transfection Reagent Kit (Roche) according to the manufacturer's instructions. Cells were incubated for 24 h at 37 °C before expression analysis by CD229 mR A quantification, flow cytometry and Western Blot.
  • Huh-7, Hep-G2, and Cos-7 cell lines were from American Type Culture Collection (ATCC).
  • Hep-G2 CD81-positive cells (Hep-G2 CD81pos) were obtained from Dr. Jean Dubuisson (Institut de Biologie de Lille, France). All the cell lines were maintained in Dulbecco's Modified Eagle's Medium (Invitrogen) supplemented with 10% fetal calf serum (PAA), 100 UI/mL penicillin, 100 ⁇ g/mL streptomycin and 2 mM L glutamine.
  • Healhy human primary hepatocytes (Lonza, Basel, Switzerland) were maintained in phenol and serum-free HBCTM Basal Medium.
  • HBCrMSingleQuots®Kit containing 500 ⁇ hEGF, 500 ⁇ transferrin, 500 ⁇ hydrocortisone, 10 mL BSA, 500 ⁇ Ascorbic Acid, 500 ⁇ GA-1000 and 500 ⁇ . insulin (Lonza) was added to basal medium.
  • Mouse anti-human monoclonal antibody directed against CD229 (clone HLy 9.1.25) conjugated to Fluorescein Isothiocyanate (FITC), unconjugated anti-CD229 (clone HLy 9.1.25) and mouse IgGl negative control were from AbD serotec (Colmar, France).
  • Mouse monoclonal anti-CD229 (clone ZY-263), mouse monoclonal anti-CD229 (clone 3H, 1998), anti-actin (clone C-l l), rabbit polyclonal anti-SR-Bl (clone H-180) were from Santa Cruz Biotechnology.
  • Mouse anti-human monoclonal antibody directed against CD81 (clone JS-81) unconjugated and conjugated to Phycoerythrin (PE) and FITC-mouse IgGl ⁇ isotype control (clone MOPC-21 ) were from BD Pharmingen.
  • PE-anti-mouse IgGl was from Beckman Coulter.
  • FITC-antimouse Occludin (clone OC-3F10) was from Invitrogen.
  • FITC-anti-goat IgG and FITC-antirabbit IgG were from Sigma- Aldrich.
  • Rabbit-anti-Claudin 1 was from Cell Signaling.
  • Unconjugated Rat-anti-E2 was a gift from Dr. Debuisson (Lille, France).
  • PE-anti- rat antibody was purchased from Jackson Immuno Research Laboratories.
  • CD229 peptides were synthesized by Genosphere.
  • the HCV serum was from HCVseropositive patients, a gift from Dr. Sandrine Castelain, (Laboratoire de Virologie, Amiens).
  • the BD Cytofix/CytopermTM Plus kit (BD Biosciences) was used for intracellular E2 stai ni ng . After two washe s i n col d PB S , c el l s were i ncub ate d i n 1 00 ⁇ ⁇ fixation/permeabilization solution during 20 min at 4 °C, and washed with BD Perm/WashTM Buffer IX containing Fetal Bovine Serum (FBS) and saponin. Then, cells were incubated with the primary anti-E2 antibody in Perm/WashTM Buffer during 30 min at 4 °C. After a wash, cells were then incubated with the secondary anti-rat-Pe antibody during 20 min.
  • FBS Fetal Bovine Serum
  • TCCAAGAAAGGACCCGGT-C-3 ' ( S E Q ID N O : 1 0 ) , HCV- AS 2 p ri m e r 5 '- TTC AAGAAAGGACCC AGTC-3 ' ( S E Q I D N O : 1 1 ), HCV-S 1 5 '- TCCCGGGAGAGCC AT AGTG-3 '(SEQ ID NO: 12) and MGB probe with 6-FAM (5 '- TCTGCGGAACCGGTG-3 ') (SEQ ID NO: 13) from Eurogentec.
  • CD229 transcripts quantification forward 5 ' -TGGGACT AAGAGCCTCTGGAAA-3 ' (SEQ ID NO: 14), reverse 5'-CCAGATGACGTTCTCAATCTC-3' (SEQ ID NO: 15) and MGB probe with 6-FAM (5'- CCCCAACAGTGGTGTC-3 ') (SEQ ID NO: 16).
  • the expression of GAPDH gene was used as housekeeping endogen control mRNA with Human GAPDH VIC-MGB from Applied Biosystems and the level of GAPDH was used to normalize the quantified mRNA.
  • HCV entry in hepatocytes represents a complex mechanism dependent on several environmental factors such as pH, temperature and other cellular factorsi.
  • the particle2-4 After an initial binding step involving molecules like GAGs and LDL-R facilitating initial attachment to the host cell, the particle2-4, through interactions with glycoproteins-El/E2 complex, interacts with SR-BI and CD8 I5-7.
  • CLDN1 and OCLDN act at a later stage and probably after a lateral migration of the virus-receptor complex to the tight junctions (TJ)s.
  • TJ tight junctions
  • HCV is internalized by clathrin-mediated endocytosis, where fusion probably occurs in early endosomesg.io.
  • the entry process seems far from being fully understood as some human cell lines expressing these receptors remain resistant to HCVn, suggesting that one or more human- specific HCV entry factor (s) remain (s) to be discovered.
  • CD229 belongs to the Signaling Lymphocytic Activation Molecule (SLAM) family, which is constituted of nine cellular receptors known to be expressed on immune cells. All members of this family possess a similar structural organization, including an extracellular domain with either two or four Ig-like domains, a single transmembrane segment and an intracytoplasmic region with tyrosine-based motifs. Unlike the other members of the SLAM family, CD229 has four rather than two extracellular Ig domains. Domains 1 and 3 are similar, as well as domains 2 and 4i3 ⁇ 4i3.
  • SLAM Signaling Lymphocytic Activation Molecule
  • CD229 is known to be the only member able to be internalized by clathrin-mediated endocytosisw. In spite of its role in the immune system, CD229 is not well known and the exact functions of this receptor remain to be elucidated. We described for the first time both the expression and functionality of CD299 in hepatocytes. The analysis of CD229 mRNA and protein sequence is similar in lymphocytes as well as hepatocytes.
  • SLAM-CD 150 was described as co-receptor for the measles virus and other morbillivirusesi5,i6.
  • the analysis of SLAM molecules expression revealed that only CD229 is expressed on hepatocytes.
  • HHPH human primary hepatocytes
  • Huh-7 and Hep-G2 cell lines express CD229 between 25 and 55%, CD81 at 60%, CLDNl and OCLDN at about 30% and few SR-BI (5%).
  • Huh-7 and Hep-G2 cells express CD229 at 20% and less than 5% respectively.
  • CLDNl is localized at TJ areas. By confocal microscopy analysis, no or few co- localizations between CD229 and CLDNl were observed, suggesting a major membrane and sub-membrane localization of CD229.
  • the amount of cell-associated virus was twice as high in CD229 P osCD81 P os as in CD229ne g CD81 P os cells.
  • the viral load released from CD229 P osCD81 pos cells was significantly 1.5 times as high as CD229negCD81 pos cells, thus showing the high HCV-susceptibility of the CD229 P o S CD81 pos sub-population.
  • siRNAs short interfering RNAs
  • the optimal effect of siRNAs was reached between 50 and 54 h after transfection, and they decreased CD229 gene expression by 98% at the most.
  • CD229 siRNAs had no effect on CD81, SR-BI and CLDN-1 expression.
  • the knockdown of CD229 by siRNA Ly9.2 and Ly9.3 resulted in a 50% inhibition of HCVcc entry.
  • CD229 over-expression was resorted to in three cell lines to study the link between high CD229 gene expression and HCV susceptibility.
  • Huh-7 line we used the human HCV-resistant Hep-G2, which does not express CD81, and the monkey kidney COS-7 cell line, which expresses CD81 at 80%, CLDNl and OCLDN at about 15% and very few SR-BI .
  • Cells were transfected with hepatic pBud-CD229 (Ly9) or the free vector control pBud (mock) (Supplementary Methods).
  • the ectopic CD229 introduction strongly increased its expression in Huh-7, Hep-G2 and COS-7 and CD81 expression remained unchange.
  • CD229 over-expression in Huh-7 tripled virus-cell attachment CD229 gene expression in Hep-G2 and Cos-7 enabled them to fix HCVcc.
  • No significant intracellular E2-fluorescence was detected at 4 h p.i. by flow cytometry.
  • the percentage of infected E2-cells as well as the E2-fluorescence intensity per cell was twice as high in Ly9-Huh-7 as in mock Huh-7 suggesting that CD229 over-expression increased HCV-Huh-7 permissiveness.
  • the intracellular viral E2 protein was detected in 10% of Ly9-Hep-G2 and Ly9-Cos-7 cells. Hence, the introduction of CD229 in these cells made them permissive to HCVcc.
  • Hep-G2 cell line Being resistant to HCV infection, the Hep-G2 cell line is the model used the most because these cells naturally do not express CD81.
  • CD229 knockdown and blocking result in an incomplete inhibition of HCVcc entry in
  • Hepatocytes polarity is relevant to HCV entry as growing evidence suggests that interplay between HCV and TJ proteins CLDN1 and OCLDN19-21 is essential for viral uptake.
  • CLDN1 and OCLDN19-21 is essential for viral uptake.
  • the hepatic CD229 was not expressed at TJ areas contrary to CL D-1 and OCLDN.
  • the virus fixation on hepatocytes did not induce CD229 co-localization with CD81 / CLDN- 1 /OCLDN.
  • CD229 could play a role at two essential steps of the viral cycle. First, we have shown its requirement in cell- virus attachment. Like GAG and LDL-R it could concentrate HCV at the cell surface allowing more effective HCVinteraction with CD81 and other late co-receptors.
  • CD229 is able to internalize, which makes us think it could play a role in HCV entry independently of the other receptors. Even if the exact role of CD229 in HCV entry is only partially elucidated, we have precisely identified the first extracellular domain of the receptor as a crucial element for attachment and virus entry and the use of peptides could contribute to the breakthrough of new preventive therapies.
  • Scavenger receptor BI is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology. 46, 1 722 3 1 (2007).
  • Tatsuo, H., Ono, N., Tanaka, K. and Yanagi, Y. SLAM (CDwl50) is a cellular receptor for measles virus. Nature. 406, 893-897 (2000).
  • Hsu, E. C, lorio, C, Sarangi, F., Khine, A. A. & Richardson, C. D. CDwl50 (SLAM) is a receptor for a lymphotropic strain of measles virus and may account for the immunosuppressive properties of this virus. Virology. 279, 9 - 2 1 (2001).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des utilisations, des méthodes et des compositions destinées à traiter une infection par un membre de la famille Flaviviridae, tel que le VHC, chez un sujet nécessitant un tel traitement. L'invention concerne plus particulièrement un agent efficace pour inhiber la liaison d'une glycoprotéine d'enveloppe du VHC (E1 ou E2) à la protéine CD229 présente sur la surface d'hépatocytes ou un inhibiteur de l'expression du gène CD229 destiné à être utilisé dans le traitement d'une infection à VHC ou dans le traitement d'une maladie associée à une infection à VHC chez un sujet nécessitant un tel traitement, telle que l'hépatite C aiguë ou chronique, ou dans la prévention de la contraction du VHC ou dans la prévention de maladies hépatiques, telles que la fibrose du foie, la cirrhose du foie ou le carcinome hépatocellulaire.
PCT/EP2012/052398 2011-02-11 2012-02-13 Méthodes et compositions pharmaceutiques pour le traitement et la prévention des infections à vhc Ceased WO2012107589A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305146.0 2011-02-11
EP11305146 2011-02-11

Publications (1)

Publication Number Publication Date
WO2012107589A1 true WO2012107589A1 (fr) 2012-08-16

Family

ID=44212025

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/052398 Ceased WO2012107589A1 (fr) 2011-02-11 2012-02-13 Méthodes et compositions pharmaceutiques pour le traitement et la prévention des infections à vhc

Country Status (1)

Country Link
WO (1) WO2012107589A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3487878A1 (fr) 2016-07-20 2019-05-29 University of Utah Research Foundation Lymphocytes car-t cd229 et leurs procédés d'utilisation

Citations (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1990007861A1 (fr) 1988-12-28 1990-07-26 Protein Design Labs, Inc. IMMUNOGLOBULINES CHIMERIQUES SPECIFIQUES CONTRE LA PROTEINE TAC p55 DU RECEPTEUR D'IL-2
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5545807A (en) 1988-10-12 1996-08-13 The Babraham Institute Production of antibodies from transgenic animals
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5585089A (en) 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
US5591669A (en) 1988-12-05 1997-01-07 Genpharm International, Inc. Transgenic mice depleted in a mature lymphocytic cell-type
US5598369A (en) 1994-06-28 1997-01-28 Advanced Micro Devices, Inc. Flash EEPROM array with floating substrate erase operation
WO1997043310A1 (fr) 1996-05-10 1997-11-20 Schering Corporation Inhibiteurs synthetiques de la protease ns3 du virus de l'hepatite c
WO1998017679A1 (fr) 1996-10-18 1998-04-30 Vertex Pharmaceuticals Incorporated Inhibiteurs de serines proteases, notamment de ns3 protease du virus de l'hepatite c
WO1998022496A2 (fr) 1996-11-18 1998-05-28 F. Hoffmann-La Roche Ag Derives peptidiques antiviraux
WO1998046597A1 (fr) 1997-04-14 1998-10-22 Emory University Inhibiteurs de serines proteases
WO1998046630A1 (fr) 1997-04-16 1998-10-22 Peptide Therapeutics Limited Inhibiteurs de protease ns3 pour l'hepatite c
JPH10298151A (ja) 1997-04-30 1998-11-10 Japan Energy Corp Ｃ型肝炎ウイルスプロテアーゼ阻害剤
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1999007733A2 (fr) 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Peptides inhibiteurs de l'hepatite c
WO1999007734A2 (fr) 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Analogues de peptides inhibiteurs de l'hepatite c
JPH11126861A (ja) 1997-10-22 1999-05-11 Nec Corp 半導体装置
WO1999032619A1 (fr) 1997-12-23 1999-07-01 The Carnegie Institution Of Washington Inhibition genetique par de l'arn double brin
WO1999038888A2 (fr) 1998-02-02 1999-08-05 Istituto Di Ricerche Di Biologia Molecolare Inhibiteurs peptidiques de l'activite de la serine protease associee a la proteine ns53 de vhc, leurs utilisations correspondantes et leur procede de production
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
WO1999050230A1 (fr) 1998-03-31 1999-10-07 Vertex Pharmaceuticals Incorporated Inhibiteurs de serine protease, particulierement de la protease ns3 du virus de l'hepatite c
JPH11292840A (ja) 1998-04-06 1999-10-26 Soyaku Gijutsu Kenkyusho:Kk ノルスタチン誘導体又はその塩
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
GB2337262A (en) 1998-03-30 1999-11-17 Hoffmann La Roche Antiviral peptide derivatives
WO1999064442A1 (fr) 1998-06-10 1999-12-16 Istituto Di Ricerche Di Biologia Molecolare P Angeletti S.P.A. Inhibiteurs peptides de la protease ns3 du virus de l'hepatite c
WO2000006529A1 (fr) 1998-07-27 2000-02-10 Istituto Di Ricerche Di Biologia Molecolare P Angeletti S.P.A. Derives de dicetoacides utilises comme inhibiteurs de polymerases
WO2000009543A2 (fr) 1998-08-10 2000-02-24 Boehringer Ingelheim (Canada) Ltd. Tri-peptides inhibiteurs de l'hepatite c
WO2000009558A1 (fr) 1998-08-10 2000-02-24 Boehringer Ingelheim (Canada) Ltd. Peptides inhibiteurs de l'hepatite c
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
WO2000020400A1 (fr) 1998-10-05 2000-04-13 Axys Pharmaceuticals, Inc. Nouveaux composes et compositions pour le traitement de l'hepatite c
WO2000031129A1 (fr) 1998-11-26 2000-06-02 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Composes pharmaceutiques inhibiteurs de la protease ns3 du virus de l'hepatite c
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
WO2000059929A1 (fr) 1999-04-06 2000-10-12 Boehringer Ingelheim (Canada) Ltd. Peptides macrocycliques actifs contre le virus de l'hepatite c
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6159938A (en) 1994-11-21 2000-12-12 Cortech, Inc. Serine protease inhibitors comprising α-keto heterocycles
WO2001002424A2 (fr) 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Inhibiteurs de la protease du virus de l'hepatite c a base d'acide boronique peptide
WO2001007407A1 (fr) 1999-07-26 2001-02-01 Bristol-Myers Squibb Pharma Company Inhibiteurs lactame de la protease ns3 du virus de l'hepatite c
US6187905B1 (en) 1998-05-06 2001-02-13 Hoffmann-La Roche Inc. Alpha-ketoamide derivatives
WO2001016357A2 (fr) 1999-08-30 2001-03-08 K.U. Leuven Research & Development Nouvelle cible pour des agents antiparasitaires et inhibiteurs de ladite cible
JP2001103993A (ja) 1999-10-05 2001-04-17 Japan Energy Corp 環状ペプチド及びセリンプロテアーゼ阻害剤
WO2001032691A1 (fr) 1999-11-02 2001-05-10 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Inhibiteurs de protease ns3 hcv
WO2001036646A1 (fr) 1999-11-19 2001-05-25 Cancer Research Ventures Limited Inhibition d"expression genique a l"aide d"arn bicatenaire
WO2001040262A1 (fr) 1999-12-03 2001-06-07 Bristol-Myers Squibb Pharma Company Inhibiteurs d'alpha-cetoamides de la protease ns3 du virus de l'hepatite c
WO2001047883A1 (fr) 1999-12-27 2001-07-05 Japan Tobacco Inc. Composes a cycles accoles et leur utilisation comme medicaments
WO2001058929A1 (fr) 2000-02-08 2001-08-16 Schering Corporation Azapeptides utiles dans le traitement de l'hepatite c
US6277830B1 (en) 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
WO2001064678A2 (fr) 2000-02-29 2001-09-07 Bristol-Myers Squibb Pharma Company Inhibiteurs de la protéase ns3 du virus de l'hépatite c
WO2001068836A2 (fr) 2000-03-16 2001-09-20 Genetica, Inc. Procedes et compositions d'interference d'arn
WO2001074768A2 (fr) 2000-04-03 2001-10-11 Vertex Pharmaceuticals Incorporated Inhibiteurs de serine proteases, notamment de la protease ns3 du virus de l'hepatite c
WO2001077113A2 (fr) 2000-04-05 2001-10-18 Schering Corporation Ns3-serine macrocyclique inhibitrice de la protease du virus de l'hepatite c, comprenant des fragments p2 n cycliques
WO2001081325A2 (fr) 2000-04-19 2001-11-01 Schering Corporation Inhibiteurs macrocycliques de la protease ns3-serine du virus de l'hepatite c comprenant des fractions p2 alkyle et aryle alanine
WO2001085172A1 (fr) 2000-05-10 2001-11-15 Smithkline Beecham Corporation Nouveaux anti-infectieux
WO2002000851A2 (fr) 2000-06-28 2002-01-03 National Research Council Of Canada Helicobacter dd-heptosyltransferase
WO2002006246A1 (fr) 2000-07-19 2002-01-24 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Acides carboxyliques de dihydroxypyrimidine utilises comme inhibiteurs de polymerases virales
WO2002008198A2 (fr) 2000-07-21 2002-01-31 Schering Corporation Nouveaux imidazolidinones comme inhibiteurs de la protease ns3-serine du virus de l'hepatite c
WO2002008251A2 (fr) 2000-07-21 2002-01-31 Corvas International, Inc. Nouveaux peptides utilises comme inhibiteurs de ns3-serine protease du virus de l'hepatite c
WO2002008244A2 (fr) 2000-07-21 2002-01-31 Schering Corporation Nouveau peptide sous forme d'inhibiteurs de protease a serine ns3 d'hepatite virale c
WO2002008256A2 (fr) 2000-07-21 2002-01-31 Schering Corporation Nouveaux peptides utilises comme inhibiteurs de serine ns3 protease du virus de l'hepatite c
WO2002008187A1 (fr) 2000-07-21 2002-01-31 Schering Corporation Nouveaux peptides utilises comme inhibiteurs de la serine protease ns3 du virus de l'hepatite c
WO2002018369A2 (fr) 2000-08-31 2002-03-07 Eli Lilly And Company Inhibiteurs peptidomimetiques de protease
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
WO2002060926A2 (fr) 2000-11-20 2002-08-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2002079234A1 (fr) 2001-03-29 2002-10-10 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Peptides et utilisation de ceux-ci en tant qu'inhibiteurs de la protease ns3 du virus de l'hepatite c
US6479508B1 (en) 2000-07-06 2002-11-12 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP1256628A2 (fr) 2001-05-10 2002-11-13 Agouron Pharmaceuticals, Inc. ARN polymerase NS5B du virus de la hepatite C et mutants derivés de la polymerase
WO2002098424A1 (fr) 2001-06-07 2002-12-12 Smithkline Beecham Corporation Nouveaux anti-infectieux
WO2002100846A1 (fr) 2001-06-11 2002-12-19 Shire Biochem Inc. Composes et methodes de traitement ou de prevention d'infections a flavivirus
WO2003000254A1 (fr) 2001-06-26 2003-01-03 Japan Tobacco Inc. Composes cycliques condenses et utilisations medicales de ceux-ci
WO2003007945A1 (fr) 2001-07-20 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de polymerase virale
WO2003010140A2 (fr) 2001-07-25 2003-02-06 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de polymerase virale
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
US6573099B2 (en) 1998-03-20 2003-06-03 Benitec Australia, Ltd. Genetic constructs for delaying or repressing the expression of a target gene
WO2003053349A2 (fr) 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Inhibiteurs de virus de l'hepatite c
WO2003064456A1 (fr) 2002-02-01 2003-08-07 Boehringer Ingelheim International Gmbh Tripeptides comprenant un hydroxyproline ether d'une quinoline substituee destines a inhiber ns3 (hepatite c)
WO2003064416A1 (fr) 2002-02-01 2003-08-07 Boehringer Ingelheim International Gmbh Tripeptides heterocycliques utiles en tant qu'inhibiteurs de l'hepatite c
WO2003066103A1 (fr) 2002-02-07 2003-08-14 Boehringer Ingelheim Pharmaceuticals, Inc. Compositions pharmaceutiques pour inhibiteurs de protease virale de l'hepatite c
US20030219893A1 (en) 2002-05-13 2003-11-27 Kansas State University Research Foundation Compositions and methods for the treatment of hepatitis C virus infection
WO2003099274A1 (fr) 2002-05-20 2003-12-04 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2003099316A1 (fr) 2002-05-20 2003-12-04 Bristol-Myers Squibb Company Sulfamides heterocycliques en tant qu'inhibiteurs du virus de l'hepatite c
WO2004032827A2 (fr) 2002-05-20 2004-04-22 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2004043339A2 (fr) 2002-05-20 2004-05-27 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c a base de cycloalkyle p1' substitue
WO2004093915A1 (fr) 2003-04-02 2004-11-04 Boehringer Ingelheim International, Gmbh Compositions pharmaceutiques contenant des inhibiteurs de protease virale de l'hepatite c
WO2004103996A1 (fr) 2003-05-21 2004-12-02 Boehringer Ingelheim International Gmbh Composes inhibiteurs de l'hepatite c
US20040258694A1 (en) 1997-10-06 2004-12-23 Chiron Spa Hepatitis C receptor protein CD81
WO2005007681A2 (fr) 2003-07-18 2005-01-27 Vertex Pharmaceuticals Incorporated Inhibiteurs de serines proteases, en particulier de la protease ns3-ns4a du vhc
WO2005028502A1 (fr) 2003-09-18 2005-03-31 Vertex Pharmaceuticals, Incorporated Inhibiteurs de serines proteases, en particulier de la protease ns3-ns4a du vhc
WO2005035525A2 (fr) 2003-09-05 2005-04-21 Vertex Pharmaceuticals Incorporated Inhibiteurs des serines proteases, en particulier de la protease ns3-ns4a du virus de l'hepatite c (vhc)
WO2005046712A1 (fr) 2003-11-12 2005-05-26 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2006000085A1 (fr) 2004-06-28 2006-01-05 Boehringer Ingelheim International Gmbh Analogues peptidiques d'inhibiteurs de l'hepatite c
WO2006067606A1 (fr) 2004-12-24 2006-06-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Derives d'uridine utilises comme medicaments antiviraux contre un virus de la famille des flaviviridae, en particulier le vhc
JP2009215280A (ja) 2008-02-14 2009-09-24 Japan Health Science Foundation 新規ｈｃｖエントリー阻害剤
WO2010035292A1 (fr) * 2008-09-24 2010-04-01 Natimab Therapeutics S.R.L. Utilisation d'un anticorps anti-vhc monoclonal humain en tant que médicament pour le traitement thérapeutique et la prévention d'infections par le vhc
WO2010039154A1 (fr) * 2008-10-05 2010-04-08 Board Of Trustees Of Leland Stanford Junior University Anticorps contre l’hépatite c et leurs utilisations
WO2010043650A2 (fr) 2008-10-14 2010-04-22 Ablynx Nv Séquences d'acides aminés dirigées contre des récepteurs cellulaires pour des virus et des bactéries

Patent Citations (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5545807A (en) 1988-10-12 1996-08-13 The Babraham Institute Production of antibodies from transgenic animals
US5591669A (en) 1988-12-05 1997-01-07 Genpharm International, Inc. Transgenic mice depleted in a mature lymphocytic cell-type
WO1990007861A1 (fr) 1988-12-28 1990-07-26 Protein Design Labs, Inc. IMMUNOGLOBULINES CHIMERIQUES SPECIFIQUES CONTRE LA PROTEINE TAC p55 DU RECEPTEUR D'IL-2
US5693761A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Polynucleotides encoding improved humanized immunoglobulins
US5585089A (en) 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
US5693762A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5598369A (en) 1994-06-28 1997-01-28 Advanced Micro Devices, Inc. Flash EEPROM array with floating substrate erase operation
US6159938A (en) 1994-11-21 2000-12-12 Cortech, Inc. Serine protease inhibitors comprising α-keto heterocycles
WO1997043310A1 (fr) 1996-05-10 1997-11-20 Schering Corporation Inhibiteurs synthetiques de la protease ns3 du virus de l'hepatite c
WO1998017679A1 (fr) 1996-10-18 1998-04-30 Vertex Pharmaceuticals Incorporated Inhibiteurs de serines proteases, notamment de ns3 protease du virus de l'hepatite c
WO1998022496A2 (fr) 1996-11-18 1998-05-28 F. Hoffmann-La Roche Ag Derives peptidiques antiviraux
WO1998046597A1 (fr) 1997-04-14 1998-10-22 Emory University Inhibiteurs de serines proteases
WO1998046630A1 (fr) 1997-04-16 1998-10-22 Peptide Therapeutics Limited Inhibiteurs de protease ns3 pour l'hepatite c
JPH10298151A (ja) 1997-04-30 1998-11-10 Japan Energy Corp Ｃ型肝炎ウイルスプロテアーゼ阻害剤
WO1999007733A2 (fr) 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Peptides inhibiteurs de l'hepatite c
WO1999007734A2 (fr) 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Analogues de peptides inhibiteurs de l'hepatite c
US20040258694A1 (en) 1997-10-06 2004-12-23 Chiron Spa Hepatitis C receptor protein CD81
JPH11126861A (ja) 1997-10-22 1999-05-11 Nec Corp 半導体装置
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
WO1999032619A1 (fr) 1997-12-23 1999-07-01 The Carnegie Institution Of Washington Inhibition genetique par de l'arn double brin
WO1999038888A2 (fr) 1998-02-02 1999-08-05 Istituto Di Ricerche Di Biologia Molecolare Inhibiteurs peptidiques de l'activite de la serine protease associee a la proteine ns53 de vhc, leurs utilisations correspondantes et leur procede de production
US6573099B2 (en) 1998-03-20 2003-06-03 Benitec Australia, Ltd. Genetic constructs for delaying or repressing the expression of a target gene
GB2337262A (en) 1998-03-30 1999-11-17 Hoffmann La Roche Antiviral peptide derivatives
WO1999050230A1 (fr) 1998-03-31 1999-10-07 Vertex Pharmaceuticals Incorporated Inhibiteurs de serine protease, particulierement de la protease ns3 du virus de l'hepatite c
JPH11292840A (ja) 1998-04-06 1999-10-26 Soyaku Gijutsu Kenkyusho:Kk ノルスタチン誘導体又はその塩
US6187905B1 (en) 1998-05-06 2001-02-13 Hoffmann-La Roche Inc. Alpha-ketoamide derivatives
WO1999064442A1 (fr) 1998-06-10 1999-12-16 Istituto Di Ricerche Di Biologia Molecolare P Angeletti S.P.A. Inhibiteurs peptides de la protease ns3 du virus de l'hepatite c
WO2000006529A1 (fr) 1998-07-27 2000-02-10 Istituto Di Ricerche Di Biologia Molecolare P Angeletti S.P.A. Derives de dicetoacides utilises comme inhibiteurs de polymerases
WO2000009558A1 (fr) 1998-08-10 2000-02-24 Boehringer Ingelheim (Canada) Ltd. Peptides inhibiteurs de l'hepatite c
WO2000009543A2 (fr) 1998-08-10 2000-02-24 Boehringer Ingelheim (Canada) Ltd. Tri-peptides inhibiteurs de l'hepatite c
WO2000020400A1 (fr) 1998-10-05 2000-04-13 Axys Pharmaceuticals, Inc. Nouveaux composes et compositions pour le traitement de l'hepatite c
US6277830B1 (en) 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
WO2000031129A1 (fr) 1998-11-26 2000-06-02 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Composes pharmaceutiques inhibiteurs de la protease ns3 du virus de l'hepatite c
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
WO2000059929A1 (fr) 1999-04-06 2000-10-12 Boehringer Ingelheim (Canada) Ltd. Peptides macrocycliques actifs contre le virus de l'hepatite c
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
WO2001002424A2 (fr) 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Inhibiteurs de la protease du virus de l'hepatite c a base d'acide boronique peptide
WO2001007407A1 (fr) 1999-07-26 2001-02-01 Bristol-Myers Squibb Pharma Company Inhibiteurs lactame de la protease ns3 du virus de l'hepatite c
WO2001016357A2 (fr) 1999-08-30 2001-03-08 K.U. Leuven Research & Development Nouvelle cible pour des agents antiparasitaires et inhibiteurs de ladite cible
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
JP2001103993A (ja) 1999-10-05 2001-04-17 Japan Energy Corp 環状ペプチド及びセリンプロテアーゼ阻害剤
WO2001032691A1 (fr) 1999-11-02 2001-05-10 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Inhibiteurs de protease ns3 hcv
WO2001036646A1 (fr) 1999-11-19 2001-05-25 Cancer Research Ventures Limited Inhibition d"expression genique a l"aide d"arn bicatenaire
WO2001040262A1 (fr) 1999-12-03 2001-06-07 Bristol-Myers Squibb Pharma Company Inhibiteurs d'alpha-cetoamides de la protease ns3 du virus de l'hepatite c
WO2001047883A1 (fr) 1999-12-27 2001-07-05 Japan Tobacco Inc. Composes a cycles accoles et leur utilisation comme medicaments
WO2001058929A1 (fr) 2000-02-08 2001-08-16 Schering Corporation Azapeptides utiles dans le traitement de l'hepatite c
WO2001064678A2 (fr) 2000-02-29 2001-09-07 Bristol-Myers Squibb Pharma Company Inhibiteurs de la protéase ns3 du virus de l'hépatite c
WO2001068836A2 (fr) 2000-03-16 2001-09-20 Genetica, Inc. Procedes et compositions d'interference d'arn
WO2001074768A2 (fr) 2000-04-03 2001-10-11 Vertex Pharmaceuticals Incorporated Inhibiteurs de serine proteases, notamment de la protease ns3 du virus de l'hepatite c
WO2001077113A2 (fr) 2000-04-05 2001-10-18 Schering Corporation Ns3-serine macrocyclique inhibitrice de la protease du virus de l'hepatite c, comprenant des fragments p2 n cycliques
WO2001081325A2 (fr) 2000-04-19 2001-11-01 Schering Corporation Inhibiteurs macrocycliques de la protease ns3-serine du virus de l'hepatite c comprenant des fractions p2 alkyle et aryle alanine
WO2001085172A1 (fr) 2000-05-10 2001-11-15 Smithkline Beecham Corporation Nouveaux anti-infectieux
WO2002000851A2 (fr) 2000-06-28 2002-01-03 National Research Council Of Canada Helicobacter dd-heptosyltransferase
US6479508B1 (en) 2000-07-06 2002-11-12 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
WO2002006246A1 (fr) 2000-07-19 2002-01-24 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Acides carboxyliques de dihydroxypyrimidine utilises comme inhibiteurs de polymerases virales
WO2002008187A1 (fr) 2000-07-21 2002-01-31 Schering Corporation Nouveaux peptides utilises comme inhibiteurs de la serine protease ns3 du virus de l'hepatite c
WO2002008256A2 (fr) 2000-07-21 2002-01-31 Schering Corporation Nouveaux peptides utilises comme inhibiteurs de serine ns3 protease du virus de l'hepatite c
WO2002008244A2 (fr) 2000-07-21 2002-01-31 Schering Corporation Nouveau peptide sous forme d'inhibiteurs de protease a serine ns3 d'hepatite virale c
WO2002008251A2 (fr) 2000-07-21 2002-01-31 Corvas International, Inc. Nouveaux peptides utilises comme inhibiteurs de ns3-serine protease du virus de l'hepatite c
WO2002008198A2 (fr) 2000-07-21 2002-01-31 Schering Corporation Nouveaux imidazolidinones comme inhibiteurs de la protease ns3-serine du virus de l'hepatite c
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
WO2002018369A2 (fr) 2000-08-31 2002-03-07 Eli Lilly And Company Inhibiteurs peptidomimetiques de protease
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
WO2002060926A2 (fr) 2000-11-20 2002-08-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2002079234A1 (fr) 2001-03-29 2002-10-10 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Peptides et utilisation de ceux-ci en tant qu'inhibiteurs de la protease ns3 du virus de l'hepatite c
EP1256628A2 (fr) 2001-05-10 2002-11-13 Agouron Pharmaceuticals, Inc. ARN polymerase NS5B du virus de la hepatite C et mutants derivés de la polymerase
WO2002098424A1 (fr) 2001-06-07 2002-12-12 Smithkline Beecham Corporation Nouveaux anti-infectieux
WO2002100846A1 (fr) 2001-06-11 2002-12-19 Shire Biochem Inc. Composes et methodes de traitement ou de prevention d'infections a flavivirus
WO2003000254A1 (fr) 2001-06-26 2003-01-03 Japan Tobacco Inc. Composes cycliques condenses et utilisations medicales de ceux-ci
WO2003007945A1 (fr) 2001-07-20 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de polymerase virale
WO2003010141A2 (fr) 2001-07-25 2003-02-06 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de polymerase virale
WO2003010140A2 (fr) 2001-07-25 2003-02-06 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de polymerase virale
WO2003053349A2 (fr) 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Inhibiteurs de virus de l'hepatite c
WO2003064456A1 (fr) 2002-02-01 2003-08-07 Boehringer Ingelheim International Gmbh Tripeptides comprenant un hydroxyproline ether d'une quinoline substituee destines a inhiber ns3 (hepatite c)
WO2003064416A1 (fr) 2002-02-01 2003-08-07 Boehringer Ingelheim International Gmbh Tripeptides heterocycliques utiles en tant qu'inhibiteurs de l'hepatite c
WO2003066103A1 (fr) 2002-02-07 2003-08-14 Boehringer Ingelheim Pharmaceuticals, Inc. Compositions pharmaceutiques pour inhibiteurs de protease virale de l'hepatite c
US20030219893A1 (en) 2002-05-13 2003-11-27 Kansas State University Research Foundation Compositions and methods for the treatment of hepatitis C virus infection
WO2003099274A1 (fr) 2002-05-20 2003-12-04 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2004043339A2 (fr) 2002-05-20 2004-05-27 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c a base de cycloalkyle p1' substitue
WO2003099316A1 (fr) 2002-05-20 2003-12-04 Bristol-Myers Squibb Company Sulfamides heterocycliques en tant qu'inhibiteurs du virus de l'hepatite c
WO2004032827A2 (fr) 2002-05-20 2004-04-22 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2004093915A1 (fr) 2003-04-02 2004-11-04 Boehringer Ingelheim International, Gmbh Compositions pharmaceutiques contenant des inhibiteurs de protease virale de l'hepatite c
WO2004103996A1 (fr) 2003-05-21 2004-12-02 Boehringer Ingelheim International Gmbh Composes inhibiteurs de l'hepatite c
WO2005007681A2 (fr) 2003-07-18 2005-01-27 Vertex Pharmaceuticals Incorporated Inhibiteurs de serines proteases, en particulier de la protease ns3-ns4a du vhc
WO2005035525A2 (fr) 2003-09-05 2005-04-21 Vertex Pharmaceuticals Incorporated Inhibiteurs des serines proteases, en particulier de la protease ns3-ns4a du virus de l'hepatite c (vhc)
WO2005028502A1 (fr) 2003-09-18 2005-03-31 Vertex Pharmaceuticals, Incorporated Inhibiteurs de serines proteases, en particulier de la protease ns3-ns4a du vhc
WO2005046712A1 (fr) 2003-11-12 2005-05-26 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2006000085A1 (fr) 2004-06-28 2006-01-05 Boehringer Ingelheim International Gmbh Analogues peptidiques d'inhibiteurs de l'hepatite c
WO2006067606A1 (fr) 2004-12-24 2006-06-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Derives d'uridine utilises comme medicaments antiviraux contre un virus de la famille des flaviviridae, en particulier le vhc
JP2009215280A (ja) 2008-02-14 2009-09-24 Japan Health Science Foundation 新規ｈｃｖエントリー阻害剤
WO2010035292A1 (fr) * 2008-09-24 2010-04-01 Natimab Therapeutics S.R.L. Utilisation d'un anticorps anti-vhc monoclonal humain en tant que médicament pour le traitement thérapeutique et la prévention d'infections par le vhc
WO2010039154A1 (fr) * 2008-10-05 2010-04-08 Board Of Trustees Of Leland Stanford Junior University Anticorps contre l’hépatite c et leurs utilisations
WO2010043650A2 (fr) 2008-10-14 2010-04-22 Ablynx Nv Séquences d'acides aminés dirigées contre des récepteurs cellulaires pour des virus et des bactéries

Non-Patent Citations (33)

* Cited by examiner, † Cited by third party
Title
"Merck Index"
"Program Manual for the Wisconsin Package", 1996
AGNELLO, V.; ABEL, G.; ELFAHAL, M.; KNIGHT, G.B.; ZHANG, Q.-X.: "Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor", PROC NATL ACAD SCI USA., vol. 96, 1999, pages 12766 - 12771
BARTOSCH, B. ET AL.: "Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B scavenger receptor", J BIOL CHEM., vol. 278, 2003, pages 41624 - 41630, XP007917959, DOI: doi:10.1074/jbc.M305289200
CLARK, W. R.: "The Experimental Foundations ofmodern Immunology", 1986, WILEY & SONS, INC.
CODING: "Biochemistry and Immunology", 1996, ACADEMIC PRESS, article "Monoclonal Antibodies: Principles and Practice: Production and Application of Monoclonal Antibodies in Cell Biology"
DE LA FUENTE M A ET AL: "Molecular characterization and expression of a novel human leukocyte cell-surface marker homologous to mouse Ly-9.", BLOOD 1 JUN 2001 LNKD- PUBMED:11369645, vol. 97, no. 11, 1 June 2001 (2001-06-01), pages 3513 - 3520, XP002648670, ISSN: 0006-4971 *
DEL VALLE JUANA M ET AL: "The cell surface expression of SAP-binding receptor CD229 is regulated via its interaction with clathrin-associated adaptor complex 2 (AP-2).", THE JOURNAL OF BIOLOGICAL CHEMISTRY 9 MAY 2003 LNKD- PUBMED:12621057, vol. 278, no. 19, 9 May 2003 (2003-05-09), pages 17430 - 17437, XP002648671, ISSN: 0021-9258 *
DEL VALLE, J.M.; ENGEL, P.; MARTIN, M.: "The cell surface expression of SAP-binding receptor CD229 is regulated via its interaction with clathrin-associated adaptor complex 2 (AP-2", J BIOL CHEM., 2003
DUBUISSON, J.; HELLE, F.; COCQUEREL, L.: "Early steps of the hepatitis C virus life cycle", CELLULAR MICROBIOLOGY, vol. 10, 2008, pages 821 - 827
ENGEL, P.; ECK, M. J.; TERHORST, C.: "The SAP and SLAM families in immune responses and Xlinked lymphoproliferative disease", NAT REV IMMUNOL., vol. 3, 2003, pages 813 - 821
EVANS, M. J. ET AL.: "Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry", NATURE, vol. 446, 2007, pages 801 - 805, XP002516759, DOI: doi:10.1038/NATURE05654
EVANS, M. J.; VON HAHN, T.; TSCHERNE, D.M.; SYDER, A.J.; PANIS, M.; WOLK, B.; HATZIIOANNOU, T.; MCKEATING, J. A.; BIENIASZ, P. D.;: "Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry", NATURE, vol. 446, 2007, pages 801 - 805, XP002516759, DOI: doi:10.1038/NATURE05654
FLINT, M.; TSCHERNE, D. M.: "Cellular receptors and HCV entry", METHODS MOL BIOL., vol. 510, 2009, pages 265 - 277
HSU, E. C.; IORIO, C.; SARANGI, F.; KHINE, A. A.; RICHARDSON, C. D.: "CDw150 (SLAM) is a receptor for a lymphotropic strain of measles virus and may account for the immunosuppressive properties of this virus", VIROLOGY, vol. 279, 2001, pages 9 - 21
KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495
KOUTSOUDAKIS, G. ET AL.: "Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses", J VIROL, vol. 80, 2006, pages 5308 - 5320
KRIEGLER: "A Laboratory Manual", 1990, W.H. FREEMAN C.O.
LINDENBACH, B. D.; EVANS, M. J.; SYDER, A. J.; WOLK, B.; TELLINGHUISEN, T. L.; LIU, C. C.; MARUYAMA, T.; HYNES, R. O.; BURTON, D.: "Complete replication of hepatitis C virus in cell culture", SCIENCE, vol. 309, 2005, pages 623 - 626, XP002993377, DOI: doi:10.1126/science.1114016
LIU, S. ET AL.: "Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection", J VIROL., vol. 83, 2009, pages 2011 - 2014, XP002669215, DOI: doi:10.1128/JVI.01888-08
MEE, C.J. ET AL.: "Effect of cell polarization on hepatitis C virus viral entry", J VIROL., vol. 82, 2008, pages 461 - 470, XP008146584, DOI: doi:10.1128/JVI.01894-07
MEERTENS, L.; BERTAUX, C.; DRAGIC, T.: "Hepatitis C Virus entry requires a criticalpostinternalization step and delivery to early endosomes via clathrin-coatedvesicles", J. VIROL., vol. 80, 2006, pages 11571 - 11578
MURRY: "Methods in Molecular Biology", vol. 7, 1991, HUMANA PRESS, INC.
PILERI, P. ET AL.: "Binding of hepatitis C virus to CD81", SCIENCE, vol. 282, 1998, pages 938 - 941, XP002092549, DOI: doi:10.1126/science.282.5390.938
PLOSS, P. ET AL.: "Human occludin is a hepatitis C virus entry factor required for infection of mouse cells", NATURE, vol. 457, 2009, pages 882 - 886, XP002669214, DOI: doi:10.1038/NATURE07684
ROITT, I.: "Essential Immunology", 1991, BLACKWELL SCIENTIFIC PUBLICATIONS
SANBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
SANDRIN, M. S.; HENNING, M. M.; LO, M. F.; BAKER, E.; SUTHERLAND, G. R.; MCKENZIE, I. F.: "Isolation and characterization of cDNA clones for Humly9: the human homologue of mouse Ly9", IMMUNOGNETICS, vol. 43, 1996, pages 13 - 19, XP009004137
TATSUO, H.; ONO, N.; TANAKA, K.; YANAGI, Y.: "SLAM (CDw150) is a cellular receptor for measles virus", NATURE, vol. 406, 2000, pages 893 - 897, XP002497367, DOI: doi:10.1038/35022579
TSCHERNE, D. M. ET AL.: "Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry", J. VIROL., vol. 80, 2006, pages 1734 - 1741
WAKITA, T. ET AL.: "Production of infectious hepatitis C virus in tissue culture from a cloned viral genome", NATURE MEDICINE, vol. 11, 2005, pages 791 - 796
WU ET AL., MOL. BIOL., vol. 294, 1999, pages 151
ZEISEL, M. B. ET AL.: "Scavenger receptor BI is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81", HEPATOLOGY, vol. 46, 2007, pages 1722 - 1731, XP007917960, DOI: doi:10.1002/hep.21994

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3487878A1 (fr) 2016-07-20 2019-05-29 University of Utah Research Foundation Lymphocytes car-t cd229 et leurs procédés d'utilisation
EP3487878A4 (fr) * 2016-07-20 2020-03-25 University of Utah Research Foundation Lymphocytes car-t cd229 et leurs procédés d'utilisation

Similar Documents

Publication Publication Date Title
KR101523391B1 (ko) 감염 및 종양 치료를 위한 조성물 및 방법
ES2961039T3 (es) Terapia combinada contra el VHB
WO2007058384A1 (fr) Procede d'inhibition de la replication du virus de l'hepatite c, inhibiteur de replication du virus et procede de selection de cet inhibiteur
JP2007503474A (ja) 遺伝子サイレンシングに有用な保存されたｈｂｖ及びｈｃｖ配列
WO2009025759A1 (fr) Protéines de jonction serrée associées à une infection et entrée du virus de l'hépatite c (vhc), procédés et utilisations de celles-ci
WO2014122660A1 (fr) Inhibiteurs de cd14 en tant que traitement efficace pour l'infection par vhc
JP7330174B2 (ja) オートファジーをモジュレーションするための方法及び医薬組成物
CN104853774B (zh) Il-20拮抗剂用于治疗肝脏疾病
WO2015009996A1 (fr) Compositions et procédés pour le traitement de l'œsophagite à éosinophiles
TW200816990A (en) Identification and characterization of HCV replicon variants with reduced susceptibility to HCV-796, and methods related thereto
WO2013024155A1 (fr) Combinaisons d'anticorps anti-facteur d'entrée de vhc et d'agents antiviraux à action directe pour le traitement et la prévention de l'infection par le vhc
JP5283106B2 (ja) Ｃ型肝炎ウイルス阻害剤
KR20240040068A (ko) 메조텔린을 특이적으로 표적화하는 조작된 면역 세포 및 이의 용도
WO2025082944A1 (fr) Inhibiteur de la famille des récepteurs de lipoprotéine de basse densité (famille ldl-r) et/ou de l'apolipoprotéine e (apoe) aux fins d'une utilisation dans le traitement d'une infection par le virus de la fièvre hémorragique de crimée-congo (cchfv)
ES3023937T3 (en) Pharmaceutical compositions for use in treating an hbv or hdv infection
CN116635422A (zh) 抗cd38抗体及其用途
Cao et al. Scavenger receptor class B type I is more conducive for genotype 1b hepatitis C virus internalization than low-density lipoprotein receptor.
US20130236480A1 (en) Transglutaminase 2 inhibitors for use in the prevention or treatment of rapidly progressive glomerulonephritis
WO2021105697A1 (fr) Traitement d'une infection par le virus de l'hépatite b (vhb)
KR101701764B1 (ko) Aam-b 발현 또는 활성 억제제를 포함하는 ｃ형 간염 예방 및 치료용 약제학적 조성물
WO2024028476A1 (fr) Méthodes de traitement de maladies médiées par th2
KR101247949B1 (ko) Ｐｉｎ1 발현 또는 활성 억제제를 포함하는 Ｃ형 간염 예방 및 치료용 약제학적 조성물
CN114391023A (zh) 用结合血小板糖蛋白IB(GPIB)α胞外结构域的化合物治疗非酒精性脂肪性肝炎(NASH)和肝细胞癌(HCC)
Aptamers 981. Modulation of Human Dendritic Cell Function Following Viral Vectors: Implications for Gene Therapy in Vaccination
Fiorentino et al. iee (IL-10R2) chain. J. Leukoc Biol 2004; 76.314–

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12704762

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12704762

Country of ref document: EP

Kind code of ref document: A1